Document:

<PAGE>
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.12

                              AMENDED AND RESTATED
                                      VIDAS
                 LICENSE, DEVELOPMENT AND COOPERATION AGREEMENT

                                 BY AND BETWEEN

                             GEN-PROBE INCORPORATED

                                       AND

                                BIOMERIEUX, INC.
<PAGE>
                              AMENDED AND RESTATED
              VIDAS LICENSE, DEVELOPMENT AND COOPERATION AGREEMENT

      This Amended and Restated VIDAS License, Development and Cooperation
agreement (the "Agreement") is entered into as of August 4, 2000 (the "Effective
Date") by and between Gen-Probe Incorporated, a Delaware corporation having its
principal place of business at 10210 Genetic Center Drive, San Diego, California
92121-1589 (hereinafter "GP"), and bioMerieux, Inc. ("BMX"), a Missouri
corporation having its principal place of business at 595 Anglum Drive,
Hazelwood, Missouri 63042-2395.

                                    RECITALS

      WHEREAS, BMX and its Affiliates maintain and operate a worldwide network
of semi-automated instruments known as "VIDAS" and "mini-VIDAS" for the
diagnosis of infectious disease and other indications; and

      WHEREAS, BMX possesses technology, knowledge, know-how and proprietary
rights pertaining to instrument systems, related microbiological know-how,
identification and susceptibility testing of microorganisms, multiple analyte
detection technologies, culture collections and specific probe and target
sequences and related intellectual property; and

      WHEREAS, GP possesses technology, knowledge, know-how and proprietary
rights pertaining to nucleic acid hybridization and amplification technologies,
detection and identification technologies (including specific probes targeting
ribosomal RNA and specific target sequences and regions), microbiological
culture collections, Probe Assay formats, specimen collection and processing,
multiple analyte detection technologies and related intellectual property; and

      WHEREAS, BMX and GP are Parties to that certain VIDAS License, Development
and Cooperation Agreement (the "VIDAS Agreement") by and between BMX and GP and
dated as of May 2, 1997 pursuant to which they, among other things, established
a joint research and development collaboration for the development of certain
Probe Assays to be processed and interpreted upon VIDAS instrumentation; and

      WHEREAS, BMX and GP desire to amend and restate the VIDAS Agreement in
order to bring to a conclusion the collaborations referred to and to provide
for, among other things, replacement of the profit-sharing arrangements set
forth in the VIDAS Agreement with a royalty arrangement and the licensing of
certain intellectual property on the terms and conditions set forth herein.

      NOW, THEREFORE, in consideration of the foregoing and the covenants and
premises contained in this Agreement, the Parties agree as follows:

                                      -1-
<PAGE>
1. DEFINITIONS

      As used in this Agreement and the accompanying Exhibits, the following
terms have the following meanings:

      1.1  "AFFILIATE" shall mean any corporation or other business entity
controlled by, controlling, or under common control with a Party hereto. For
purposes of this definition, "control" shall mean direct or indirect ownership
of more than fifty percent (50%) of the voting interest or income interest in a
corporation or entity or such relationship as, in fact, constitutes actual
control. An Affiliate shall lose its status as such, prospectively, upon a
Change in Control of such Affiliate which causes the Party's direct or indirect
ownership interest to become fifty percent (50%) or less.

      1.2  "ASSAY" shall mean a diagnostic process or procedure applied to a
sample, or a portion of a sample, whereby a particular chemical compound, or a
collection of compounds, or a portion of a chemical compound, is detected and
optionally quantified.

      1.3  "BMX TECHNOLOGY" shall mean:

            (a) the patents and patent applications in existence as of May 2,
      1997, and which BMX owned or which were licensed to BMX (with right to
      sublicense or otherwise transfer) as of May 2, 1997, together with any
      divisionals, continuations, continuations-in-part, reissues, renewals,
      substitute applications and inventors' certificates which issue from
      applications filed after May 2, 1997 with respect to any of the foregoing
      patents or patent applications and claim priority therefrom, and any
      counterparts of any of the foregoing filed in any other jurisdiction.
      (Pursuant to the VIDAS Agreement, BMX provided a list of the foregoing in
      a confidential annex furnished under a confidentiality agreement dated
      April 30, 1997 between GP and BMX.);

            (b) the ideas, inventions, Confidential Information, devices, trade
      secrets, procedures, methods, data, studies, reports, processes, rights,
      manufacturing information, and other information that is generally not
      known that affords BMX a competitive advantage with respect to its
      business ("KNOW-HOW"), each to the extent it is useful in practicing the
      patents and patent applications referred to in subparagraph (a) above and
      each to the extent that it existed as of May 2, 1997;

            (c) any technology which existed prior to the Effective Date hereof
      and constituted BMX Core-Related Collaboration Technology or BMX
      Collaboration Technology under the definitions of the VIDAS Agreement; and

            (d) Any Derivative Invention made by BMX after the Effective Date
      hereof.

      1.4  "CALENDAR QUARTER" shall mean, for each Calendar Year, the quarter
beginning on each January 1, April 1, July 1 or October 1 of such year, without
regard to whether such dates are otherwise business days.

                                      -2-
<PAGE>
      1.5  "CALENDAR YEAR" shall mean any calendar year commencing on January 1
and ending on December 31.

      1.6  "CHANGE IN CONTROL" shall mean, with respect to a Party, (a) the
acquisition of such Party by another entity by means of any transaction or
series of related transactions (including, without limitation, any
reorganization, merger or consolidation, but excluding any merger effected
exclusively for the purpose of changing the domicile of such Party); (b) the
sale, transfer or other disposition of all or substantially all of the assets of
such Party (including without limitation all of its assets relating to this
Agreement); or (c) the sale of all or substantially all of the capital stock of
such Party; unless in each of clauses (a) through (c) above, such Party's
stockholders of record immediately prior to such acquisition or sale hold (by
virtue of the securities issued in consideration for such Party's acquisition or
sale or otherwise) greater than fifty percent (50%) of the total voting power of
the surviving or acquiring entity.

      1.7  "CLINICAL TRIAL COSTS" shall mean actual financial obligations
incurred to Third Parties (e.g., costs of sample acquisition, patient
recruitment and follow-up, and data analysis) necessarily incurred by BMX, or
for its account, for any clinical trial of any Initial VIDAS Product.

      1.8  "COMMERCIALLY REASONABLE EFFORTS" shall mean that level of effort
which would be devoted by an independent entity reasonably seeking to pursue a
profit-making business, in light of all of the relevant circumstances actually
faced by the Party charged with the duty to use such efforts.

      1.9  "CONFIDENTIAL INFORMATION" shall mean all information and materials,
patentable or otherwise, of a Party which are not generally known or available,
are treated as private and confidential by the disclosing Party and are
disclosed by or on behalf of such Party to the other Party pursuant to this
Agreement, including, but not limited to, formulations, techniques, methodology,
equipment, data, reports, Know-How, preclinical and clinical trials and the
results thereof, sources of supply, patent positioning and business plans,
including any negative developments, whether or not related to VIDAS Products
and VIDAS Instrumentation.

      1.10  "DERIVATIVE INVENTION" shall have the meaning ascribed in Section
7.3.

      1.11  "FDA" shall mean the United States Food and Drug Administration.

      1.12  "FIRST COMMERCIAL SALE" of a VIDAS Product shall mean the first sale
for use or consumption of such VIDAS Product to a Third Party after Regulatory
Approval (if required by law) has been granted by the governing health
regulatory authority of the country or political subdivision in which such sale
occurs. Sale to an Affiliate shall not constitute a First Commercial Sale unless
the Affiliate is the end user of the VIDAS Product.

      1.13  "FORCE MAJEURE" shall have the meaning ascribed in Section 16.3.

                                      -3-
<PAGE>
      1.14  "FTE" shall mean the equivalent of a full-time researcher's or
program manager's work time expended on activities pursuant to approved Work
Plans over a 12-month period (including normal vacations, sick days and
holidays).

      1.15  "FULLY-ABSORBED MANUFACTURING COST" shall mean, with respect to any
Key Biochemistry Components ("KBC's") manufactured by GP pursuant to Article 8
of this Agreement:

            (a) the price paid or other cost incurred for any product, component
      or raw material acquired for incorporation into such KBCs; and

            (b) the following specified costs of manufacturing or incorporating
      such products, components or raw materials into the relevant KBC in
      applicable form: (i) direct manufacturing and quality control costs
      related to an individual KBC (i.e., those costs which vary with
      production), including, without limitation, direct labor and benefit
      expenses for manufacturing personnel, actual cost of raw materials,
      components, consumable bulk, costs associated with scrap and other
      production materials incorporated into such KBC, plus (ii) fixed
      manufacturing overhead costs allocable to the KBC based on actual
      utilization for manufacturing work directly related to such KBC conducted
      at the relevant manufacturing facility, including, but not limited to,
      direct benefit and labor expenses for technical services and support
      services, depreciation, maintenance and repairs and insurance costs
      associated with such utilization of the manufacturing facility, plus (iii)
      any and all royalties payable for rights used in the manufacture of a KBC
      sold by GP (provided that as to all such royalties known to GP on the
      Effective Date, such royalties shall have been disclosed in writing to
      BMX), in each case in accordance with GAAP and consistent with applicable
      Exhibits to the VIDAS Agreement, and subject to verification on audit by
      BMX pursuant to Section 8.1(e).

Manufacturing overhead of GP hereunder shall be based upon substantially the
same cost structures as are used for the same or similar materials, components
or products, which are used by GP in its business operations outside the scope
of this Agreement.

      1.16  "GAAP" shall mean United States Generally Accepted Accounting
Principles, consistently applied.

      1.17  "GP TECHNOLOGY" shall mean:

            (a) the patents and patent applications in existence as of May 2,
      1997 and which GP owned or which were licensed to GP (with right to
      sublicense or otherwise transfer) as of May 2, 1997, together with any
      divisionals, continuations, continuations-in-part, reissues, renewals,
      substitute applications and inventors' certificates which issue from
      applications filed after May 2, 1997 with respect to any of the foregoing
      patents or patent applications and claim priority therefrom, and any
      counterparts of any of the foregoing filed in any other jurisdiction.
      (Pursuant to the VIDAS Agreement, GP provided a list of the foregoing in a
      confidential annex furnished under a confidentiality agreement dated April
      30, 1997 between GP and BMX.)

                                      -4-
<PAGE>
            (b) the ideas, inventions, Confidential Information, devices, trade
      secrets, procedures, methods, data, studies, reports, processes, rights,
      manufacturing information, and other information that is generally not
      known that affords GP a competitive advantage with respect to its business
      ("Know-How"), each to the extent it is useful in practicing the patents
      and patent applications referred to in subparagraph (a) above and each to
      the extent that it existed as of May 2, 1997;

            (c) any technology which existed prior to the Effective Date hereof
      and constituted GP Core-Related Collaboration Technology or GP
      Collaboration Technology under the definitions of the VIDAS Agreement; and

            (d) any Derivative Invention made by GP after the Effective Date
      hereof.

For the avoidance of doubt, GP and BMX agree that nothing contained herein shall
give BMX any rights to GP's hybridization protection assay ("HPA") and/or
acridinium ester labeling technologies for use in VIDAS Products. For the
avoidance of doubt, GP and BMX agree that BMX shall have the right under this
Agreement to purchase from GP, pursuant to Article 8 (and in particular Section
8.2(e)), hybridization protection assays ("HPA") using acridinium ester labeling
technologies, which shall be used by BMX solely for product development of VIDAS
Products and for quality control of VIDAS Products (in a manner consistent with
the prior use of such technologies for such product development and quality
control purposes by GP in connection with the VIDAS Agreement). Nothing
contained herein shall permit BMX to include HPA or acridinium ester labeling
technologies in VIDAS Products.

    1.18 "KEY BIOCHEMISTRY COMPONENTS" or "KBCs" shall mean: (a) the lysing
tubes, enzymes, nucleic acids and other biochemical compounds and reagents
identified on Exhibit A hereto.

    1.19 "NET SALES" shall mean the gross amount invoiced to Third Party end
users by BMX, its Affiliates, and distributors for all VIDAS Products sold
(except to the extent an Affiliate is the end user of such VIDAS Products, in
which case the gross amount invoiced therefor shall be deemed to be the amount
that would be invoiced to a Third Party in an arms length transaction) after
deduction for the following items (i) trade, quantity and cash discounts or
rebates actually allowed, paid or taken; (ii) credits, rebates, charge-back
rebates or reimbursements actually granted or given to wholesalers and other
distributors, buying groups, health care insurance carriers, governmental
agencies and other institutions; (iii) credits or allowances actually granted or
given for rejection or return of such VIDAS Products previously sold; (iv) any
tax, tariff, duty or other governmental charge (other than an income tax) levied
on the sale, transportation or delivery of VIDAS Products and actually and
finally borne by the seller thereof; and (v) any charge for freight or insurance
actually and finally borne by the seller thereof.[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -5-
<PAGE>
      [***]

      1.20 "OPTION TARGET" shall mean any of the Assay targets listed on Exhibit
B hereto, to the extent any such target has been designated as such by BMX in
accordance with Section 6.8 hereof.

      1.21 "PARTY" shall mean BMX or GP; "PARTIES" shall mean BMX and GP.

      1.22 "PROBE ASSAY" shall mean an Assay using a nucleic acid as a necessary
and active reagent or which detects a set of nucleic acid sequences or a
specific nucleic acid sequence, as a means of obtaining useful information
relevant to the sample being assayed.

      1.23 "PRODUCT LIABILITY CLAIMS" shall have the meaning ascribed in Section
8.6(b).

      1.24 "REGULATORY APPROVAL" shall mean all approvals (including price and
reimbursement approvals), licenses, registrations or authorizations of any
country, federal, state or local regulatory agency, department, bureau or other
government entity that are necessary for the use, storage, import, transport
and/or sale of a VIDAS Product in a country or other political subdivision.

      1.25 "ROYALTY TERM" shall mean the period of time commencing on the First
Commercial Sale of any VIDAS Product and ending upon the later of:

            (a) ten (10) years;

            (b) the date on which all of the Patents registered in the United
            States, Japan, France, Italy, or Germany and covering any portion of
            the GP RNA Technology and/or the GP TMA Technology used in the
            Product for which a royalty is to be computed have expired; and

            (c) the date on which all of the Patents registered in the country
            of sale (without considering the patents for GP RNA Technology and
            the GP TMA Technology), and used in the Product for which a royalty
            is to be computed, have expired.

      1.26 "SAMPLE COLLECTION KIT" shall have the meaning ascribed in Section
8.3(a).

      1.27 "THIRD PARTY" shall mean any person or entity other than BMX or GP or
any of their Affiliates.

                                      -6-

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
      1.28 "TRANSITION PERIOD" shall mean the period beginning on the Effective
Date and ending December 30, 2000 (unless extended pursuant to the terms of this
Agreement).

      1.29 "VIDAS AGREEMENT" shall mean that certain VIDAS License, Development
and Cooperation Agreement by and between BMX and GP dated as of May 2, 1997.

      1.30 "VIDAS FIELD" shall mean:

               (a) the detection, identification, quantification, and/or
        susceptibility testing of agents causing human clinical infectious
        diseases, as present in the human body, solely for the purpose of
        diagnosis and medical care of the persons from whom the tested samples
        were taken;

               (b)    testing for sequences encoding [***];

               (c) testing for microorganisms in any and all materials
        associated with the production (including quality control) of foodstuffs
        or beverages (including water) intended for human or animal consumption;

               (d) testing for any analyte listed on Exhibit B and selected by
        BMX pursuant to Section 6.8, as present in a clinical sample from the
        human body, solely for the purpose of diagnosis and medical care of the
        person from whom the tested sample was taken.

The VIDAS Field specifically does not include testing for infectious agents in
blood and blood products intended for transfusion, or the testing for infectious
agents in blood in connection with organ transplants, or the testing of
specimens from non-human animals or environmental sources except as specifically
provided above, even if such testing is for the purpose of detecting or
identifying organisms which are associated with infectious diseases in man.

    1.31 "VIDAS INSTRUMENTATION" shall mean, collectively, the BMX instrument
system currently known as the "VIDAS" system and the BMX instrument system
currently known as the "mini-VIDAS" system, as such systems existed on the date
of the VIDAS Agreement and as hereafter modified or supplemented by additional
instrumentation or devices as required to accommodate VIDAS Products, each of
which modified and/or supplemented systems shall consist of instrumentation
which is generally sold for processing and interpreting both Probe Assays and
immunoassays (excluding, in any event, all VIDAS Products to be run on such
instrumentation); provided, however, that such term may include a Probe
Assay-only VIDAS system that BMX may elect to develop at its expense, and
provided, further, such modified and/or supplemented Probe Assay-only
instrumentation system shall:

            (a) [***];

                                      -7-

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
            (b) use as its test format (i) a multi-well plastic cassette
      (currently referred to as a "VIDAS strip") which contains pre-dispensed
      reagents, tests for analytes and controls which is manually loaded into
      and resident in individual incubation and processing slots, and (ii) a
      pipette tip (currently referred to as an "SPR") containing immobilized
      capture ligands; and

            (c) accommodate, on any single unit capable of stand-alone operation
      of such modified and/or supplemented instrument system, no more than
      [***] test cassettes at one time.

      1.32 "VIDAS PRODUCTS" shall mean the following Probe Assays, in each case
made, used, or sold under the license granted by GP in this Agreement and solely
and exclusively for use on VIDAS Instrumentation:

               (a) "VIDAS INITIAL PRODUCTS", which shall mean, collectively,
        Probe Assays for the detection of [***], Probe Assays for the detection
        of [***], Probe Assays for the detection of [***], and Probe Assays for
        the detection of [***];

               (b) "VIDAS QHIV PRODUCT", which shall mean the Probe Assay for
        the [***] detection of human immunodeficiency virus which has been the
        subject of [***]. IF BMX elects to develop an alternative QHIV probe
        assay for the VIDAS Instrumentation and a new regulatory submission is
        required for such assay, then (i) if BMX ceases to market the original
        VIDAS QHIV Product and markets only the alternative QHIV probe assay,
        such alternative QHIV probe assay shall thereafter be prospectively
        considered to be the VIDAS QHIV Product for purposes of this Agreement,
        but (ii) if BMX continues to market the original VIDAS QHIV Product and
        also markets the alternative QHIV probe assay, such alternative QHIV
        probe assay shall be considered to be a VIDAS Future Infectious Disease
        Product for purposes of this Agreement.

               (c) "VIDAS HLA PRODUCT", which shall mean Probe Assays for the
        detection and quantification of sequences encoding [***];

               (d) "VIDAS FOOD TESTING PRODUCTS", which shall mean Probe Assays
        for the detection of microorganisms in any and all materials associated
        with the production (including quality control) of foodstuffs or
        beverages (including water) intended for human or animal consumption;

               (e) "VIDAS FUTURE INFECTIOUS DISEASE PRODUCTS", which shall mean
        Probe Assays, other than the VIDAS Initial Products and VIDAS QHIV
        Product, for detection, identification, quantification of, and/or
        susceptibility testing for agents causing human clinical infectious
        diseases, as present in the human body, solely for the purpose of
        diagnosis and medical care of the persons from whom the tested samples
        were taken;

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

                                      -8-

<PAGE>
            (f) "VIDAS OTHER FUTURE PRODUCTS", which shall mean any Probe Assays
      which are directed at one or more Option Targets selected by BMX pursuant
      to Section 6.8 hereof.

                                      -9-
<PAGE>
2. TERMINATION OF PRIOR RELATIONSHIP

      It is the Parties' intention by the adoption of this Agreement to
prospectively terminate, as of the Effective Date, the collaborative
relationship established by the VIDAS Agreement and to substitute in its place
the new relationship provided for in this Agreement. The VIDAS Agreement shall
not apply to the activities of the Parties occurring after the Effective Date,
except as specifically stated in this Agreement, and the terms of this Agreement
shall prospectively supersede the terms of all prior related understandings and
agreements between the parties (including, without limitation, the VIDAS
Agreement) as of the Effective Date, except where the terms of such prior
related understandings or agreements are expressly and specifically incorporated
by reference into this Agreement. For the avoidance of doubt, and
notwithstanding any other provision of this Agreement, nothing contained herein
shall negate or diminish any obligation of a Party to preserve the
confidentiality of any confidential information obtained by that Party from the
other Party pursuant to a prior agreement between the Parties.

      2.1 TERMINATION OF VIDAS DEVELOPMENT PROGRAMS. The joint development
programs described in Article II of the VIDAS Agreement are hereby terminated,
except to the extent specifically set forth herein.

      2.2 TERMINATION OF VIDAS FUNDING OBLIGATIONS. The funding obligations
described in Article III of the VIDAS Agreement are hereby terminated, except to
the extent specifically set forth herein.

                                      -10-
<PAGE>
3. RIGHTS, LICENSES, AND RESTRICTIONS

      3.1 LICENSE GRANTS BY GP. Subject to the terms and conditions of this
Agreement, GP hereby grants to BMX a non-exclusive, non-transferable (except to
Affiliates), royalty-bearing (as set forth in Article 4) worldwide license in
the VIDAS Field to use the GP Technology solely to develop, make and have made,
use, sell, offer for sale, have sold and import the VIDAS Products, solely and
exclusively for use on the VIDAS Instrumentation.

      3.2 LICENSE GRANTS BY BMX. BMX hereby grants to GP a non-exclusive, non-
transferable, fully-paid license under the BMX Technology to the extent
necessary or appropriate to permit GP to perform its limited obligations
pursuant to Article 6 ("Product Development Transition").

      3.3 BMX RIGHTS IN GP MAGNETIC SEPARATION DEVICE. GP agrees that BMX shall
have the right to purchase from GP, for use with VIDAS Instrumentation, the
magnetic separation device used for target capture that has been developed by GP
prior to the date of this Agreement and disposable supplies used with such
magnetic separation device. The purchase price to be paid by BMX to GP for each
magnetic separation device shall be [***]. Additionally, GP agrees that BMX
shall have the right to contract directly with the manufacturers of the magnetic
separation device or associated disposables with respect to the possible
development of an alternative magnetic separation device or disposables. Nothing
contained herein shall require GP to consent to the disclosure by any such
manufacturer of any GP Confidential Information to BMX.

      3.4 DISCLOSURE OF TECHNOLOGY. Subject to the confidentiality requirements
of Article 12 and the express limitations of Article 8, promptly following the
Effective Date and from time to time as necessary, GP shall disclose to BMX such
GP Technology as is licensed to BMX hereunder and GP shall promptly provide to
BMX all information resulting from GP's work in the collaboration under the
VIDAS Agreement that may be necessary or useful for BMX to carry on the
development, manufacture, and sale of the VIDAS Products. Subject to the
confidentiality requirements of Article 12, promptly following the Effective
Date and from time to time as necessary, BMX shall disclose to GP such BMX
Technology as is licensed to GP hereunder. For the avoidance of doubt, nothing
contained in this Section 3.4 shall be construed to require GP to disclose to
BMX GP's hybridization protection assay ("HPA") and/or acridinium ester labeling
technologies.

      3.5 PATENT MARKING. BMX agrees that it will duly mark all VIDAS Products
made, used, offered for sale, sold, or imported under the terms of this
Agreement with the patent number or numbers of any applicable GP Patents
practiced thereby, in a manner reasonably intended to comply with the
requirements for providing constructive notice under applicable patent laws.

      3.6 NO OTHER TECHNOLOGY RIGHTS. Except as otherwise expressly provided in
this Agreement, under no circumstances shall a Party, as a result of this
Agreement, obtain any ownership interest or other right in any discovery,
invention or other technology, data or information (or any patent, copyright,
trademark, or other intellectual property rights

***  Certain information on this page has been omitted and filed separately with
     the Commission. Confidential treatment has been requested with respect to
     the omitted portions.

                                      -11-

<PAGE>
therein) of the other Party, including items that may be transferred by the
other Party to such Party at any time pursuant to this Agreement. Except as
expressly provided in this Agreement, neither Party shall be under any
obligation to grant to the other Party any rights in any patent, copyright,
trademark, or other intellectual property nor under any restriction with respect
thereto; provided, however, that if use of any GP trademark is required for sale
of any VIDAS Product by reason of the inclusion in such Product of any GP
Technology or component, the same shall be authorized by GP.

      3.7 LIMITATION ON REVERSE ENGINEERING. Nothing in this Agreement shall be
interpreted as giving a Party the right to analyze, dissect, or disassemble any
instrument, reagent, component, object, software or other property of the other
Party provided under the terms of this Agreement, and which is not properly
available from other sources which have the right to transfer such property and
authorize such activity, in order to circumvent the need for a license of the
technology reflected therein. The licenses granted hereunder do not include a
license for research and development activities which are intended to identify
means by which the need for the license can be avoided.

      3.8 NO RESTRICTION ON COLLABORATION WITH THIRD PARTIES. Neither BMX nor GP
shall be restricted from entering into any collaboration with any Third Party in
the Field or outside the Field (or any portion thereof). Nothing contained in
this Section shall independently permit assignment of any rights and/or
obligations of this Agreement by any Party in connection with any collaboration.

      3.9 RESERVATION OF RIGHTS TO GP TECHNOLOGY. Except for the licenses
expressly granted by GP to BMX under section 3.1, no right, title, or interest
in or to the GP Technology shall pass from GP to BMX under this Agreement or
otherwise vest in or become the property of BMX. GP shall retain the
unrestricted right to use and/or license for use the GP Technology for any
purpose whatsoever, inside or outside the VIDAS Field.

      3.10 RESERVATION OF RIGHTS TO BMX TECHNOLOGY. Except for the licenses
expressly granted by BMX to GP under section 3.2, no right, title, or interest
in or to the GP Technology shall pass from BMX to GP under this Agreement or
otherwise vest in or become the property of GP. BMX shall retain the
unrestricted right to use and/or license for use the BMX Technology for any
purpose whatsoever, inside or outside the VIDAS Field.

      3.11 RECOGNITION OF STANFORD AND ORGANON TEKNIKA AGREEMENTS. The rights
granted to BMX by GP hereunder are subject to the following:

            (a) Stanford Agreement. The patent rights designated as "Selective
Amplification", U.S. Patent No. 5,537,990 are sublicensed to BMX by GP under
the terms of a co-exclusive license agreement (the "Stanford Agreement")
effective April 27, 1997 between Gen-Probe and The Board of Trustees of the
Leland Stanford Junior University, Palo Alto, California ("Stanford"). Under
the terms of the Stanford Agreement, certain provisions as set forth in
Schedule H, attached hereto, are incorporated into this Agreement by reference.

            (b) Teknika Agreement. GP is a party to a non-assertion agreement

                                      -12-

<PAGE>
      effective February 7, 1997 (the "Teknika Agreement") with Organon Teknika
      B.V., having a place of business at Boseind 15, 5281 RM Boxtel, The
      Netherlands ("Teknika"), which agreement grants certain rights and imposes
      certain conditions with respect to the transcription-based amplification
      patent rights owned or licensed by GP. BMX agrees, at the request of
      Teknika, to permit and to cooperate fully with an annual review of its
      manufacturing records (and such other records as may be required) by an
      impartial, technically qualified third party to verify compliance with the
      provisions of Section 3.3 of the Teknika Agreement. Selection of such
      third party shall be subject to the approval of BMX, such approval to be
      not unreasonably withheld. The results of such a review as provided to
      Teknika will consist solely of a finding of compliance or non-compliance.
      The cost of such review shall be born by Teknika and shall not be
      unreasonably burdensome for BMX.

      (c) CONTINUATION OF RIGHTS. In the event the Stanford Agreement or Teknika
      Agreement is terminated for any reason, the rights under such agreements
      which are granted by GP to BMX under this Agreement, as applicable, may be
      continued with Stanford and/or Teknika, as applicable, provided that
      certain conditions precedent, as set forth in Exhibit H, shall have been
      fulfilled.

                                      -13-
<PAGE>
4. FEES AND PAYMENTS

      4.1 EARNED ROYALTIES. In exchange for the rights granted BMX by this
Agreement, BMX agrees to make the following earned royalty payments to GP:

            (a) VIDAS INITIAL PRODUCTS -- UNITED STATES, CANADA, AND JAPAN. BMX
      shall pay to GP a royalty on annual Net Sales of Initial VIDAS Products in
      the United States, Canada, and Japan as follows:

                  (i)     [***] of annual Net Sales for that portion of such Net
                          Sales that is less than or equal to [***];

                  (ii)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iii)   [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***]; and

                  (iv)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***].

            (b) VIDAS QHIV PRODUCT -- UNITED STATES, CANADA, AND JAPAN. BMX
      shall pay to GP a royalty on annual Net Sales of VIDAS QHIV Products in
      the United States, Canada, and Japan as follows:

                  (i)     [***] of annual Net Sales for that portion of such Net
                          Sales that is less than or equal to [***];

                  (ii)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iii)   [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iv)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***]; and

                  (v)     [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***].

            (c) VIDAS INITIAL PRODUCTS AND VIDAS QHIV PRODUCT -- REST OF THE
      WORLD. BMX shall pay to GP a royalty on annual Net Sales of Initial VIDAS
      Products in all countries other than the United States, Canada, and Japan
      as follows:

      *** Certain information on this page has been omitted and filed separately
      with the Commission. Confidential treatment has been requested with
      respect to the omitted portions.

                                      -14-
<PAGE>
                  (i)     [***] of annual Net Sales for that portion of such Net
                          Sales that is less than or equal to [***];

                  (ii)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iii)   [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iv)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***]; and

                  (v)     [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***].

            (d) VIDAS FOOD TESTING PRODUCTS - WORLDWIDE. BMX shall pay to GP a
      royalty on worldwide annual Net Sales of VIDAS Food Testing Products as
      follows:

                  (i)     [***] of annual Net Sales for that portion of such Net
                          Sales that is less than or equal to [***];

                  (ii)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***];

                  (iii)   [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***] and less than or
                          equal to [***]; and

                  (iv)    [***] of annual Net Sales for that portion of such Net
                          Sales that is in excess of [***].

            (e) VIDAS HLA PRODUCTS, VIDAS FUTURE INFECTIOUS DISEASE PRODUCTS,
      AND VIDAS OTHER FUTURE PRODUCTS - WORLDWIDE. BMX shall pay to GP a royalty
      of [***] on worldwide annual Net Sales of VIDAS HLA Products, VIDAS Future
      Infectious Disease Products, and VIDAS Other Future Products.

            (f) ROYALTY TERM. Earned Royalties for sales of any VIDAS Product in
      a given country shall be paid for a period equal to the Royalty Term for
      such product in such country.

      *** Certain information on this page has been omitted and filed separately
      with the Commission. Confidential treatment has been requested with
      respect to the omitted portions.

                                      -15-
<PAGE>
      4.2 MINIMUM ANNUAL ROYALTIES. Beginning January 1, 2002, BMX shall pay to
GP a minimum annual royalty as follows:

<TABLE>
<S>                                                                  <C>
2002 .............................................................   [***]

2003 .............................................................   [***]

2004 through 2010 ................................................   [***]
</TABLE>

The minimum annual royalty for each year shall accrue as of January 1 in that
year. To the extent that earned royalties paid for such year are not equal to or
more than the minimum royalty for that year, then at the time of BMX's report
and payment for the fourth Calendar Quarter BMX shall pay to GP the amount
necessary to make the total royalty payments equal the minimum annual royalty.
If BMX terminates this Agreement pursuant to and in accordance with Section
13.2, BMX shall not have any obligation or liability with respect to any minimum
annual royalty which had not accrued as of the termination date. Each minimum
annual royalty shall be creditable against earned royalties that accrue under
this Agreement in any calendar year before 2011.

      4.3 THIRD PARTY ROYALTIES. BMX shall be solely responsible for payment of
all royalties due to Third Parties from either GP or BMX in connection with the
development, manufacture, use or sale of VIDAS Products; provided, however, as
follows:

            (a) VIDAS QHIV PRODUCT -- UNITED STATES, CANADA, AND JAPAN. In the
      event that BMX is required to obtain a license from a Third Party in
      respect of any patents that are necessary to develop, make, have made,
      use, sell, have sold or import VIDAS QHIV Products in the United States,
      Canada, or Japan, then BMX may reduce the royalty otherwise owing on Net
      Sales of such product in such country by [***] of the royalty payments
      made under such Third Party license up to a maximum reduction of [***] of
      Net Sales of such VIDAS QHIV Product in such country; and provided,
      further, that the effective royalty rate payable under the applicable
      provision of this Agreement during any quarter shall not be reduced to
      less than [***] of Net Sales in such country.

            (b) VIDAS INITIAL PRODUCTS AND VIDAS QHIV PRODUCT -- REST OF THE
      WORLD. In the event that BMX is required to obtain a license from a Third
      Party in respect of any patents covering intellectual property (patents or
      proprietary rights) that is necessary to develop, make, have made, use,
      sell, have sold or import either VIDAS Initial Products or VIDAS QHIV
      Products in any country other than the United States, Canada, or Japan,
      then BMX may reduce the royalty otherwise owing on Net Sales of such
      product in such country by [***] of the royalty payments made under such
      Third Party license up to a maximum reduction of [***] of Net Sales of
      such VIDAS Initial Products or VIDAS QHIV Product, as applicable, in such
      country; and provided, further, that the effective royalty rate payable
      under the applicable provision of this Agreement during any quarter shall
      not be reduced to less than [***] of Net Sales in such country.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -16-
<PAGE>

            (c) Collins Patent Royalties - In the event that BMX is required to
      obtain a license to United States Patents No. 5,780,224 or No. 5,750,338,
      foreign counterparts thereto, or other patents and applications claiming
      priority therefrom, in order to develop, make, have made, use, sell, have
      sold or import a VIDAS Product in any country, then in addition to the
      royalty reductions provided above, BMX may reduce the royalty otherwise
      owing on Net Sales of such product in such country by [***] of any running
      royalty payments made under such license, up to [***] of Net Sales of such
      VIDAS Product in such country; provided that

                  (i)     The effective royalty rate payable under the
                          applicable provision of this Agreement during any
                          quarter in any country as to any VIDAS Product
                          referred to in subparagraphs 4.1(b) though 4.1(d)
                          above shall not be reduced to less than the minimum
                          royalty rate set forth for such product in such
                          subparagraphs, except that in the case of sales of the
                          VIDAS QHIV Product in the United States, Canada, and
                          Japan only, the effective royalty shall not be reduced
                          to less than [***]

                  (ii)    In the case of sales of any VIDAS Initial Product in
                          the United States, Canada, and/or Japan only, BMX may
                          reduce the royalty otherwise owing on Net Sales of any
                          such product by the entire amount of any running
                          royalty payments made under such Collins Patent
                          License for such country, up to a maximum reduction of
                          [***] of Net Sales of such VIDAS Initial Product in
                          such country; provided that the effective royalty
                          shall not be reduced to less than [***].

      4.4 COMPLETION OF ROYALTY TERM. Upon the conclusion of the Royalty Term,
BMX's licenses hereunder shall be deemed to be fully paid-up.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -17-
<PAGE>
5. PAYMENTS; RECORDS; AUDITS

      5.1 PAYMENTS; REPORTS. Royalty payments and reports for the sale of VIDAS
Products shall be calculated and reported for each Calendar Quarter by each of
BMX and its Affiliates. All royalty payments due to a Party under this Agreement
shall be paid within sixty (60) days of the end of each Calendar Quarter, unless
otherwise specifically provided herein. Each payment of royalties shall be
accompanied by a report of Net Sales of VIDAS Products, on a country-by-country
basis, showing for each country the breakdown among BMX and its Affiliates, in
sufficient detail to permit confirmation of the accuracy of the royalty payment
made, including, without limitation, the number of VIDAS Products sold, the
gross sales and Net Sales of VIDAS Products, the amount of each category of
deduction from Net Sales specified in the definition thereof in Article 1, the
royalties, in U.S. dollars, payable, the method used to calculate the royalty
and the exchange rates used. The report provided pursuant to this paragraph
shall be treated as Confidential Information under this Agreement and shall only
be used or made available to GP employees for purposes of verifying that proper
Royalty payments have been made by BMX.

      5.2 EXCHANGE RATE; MANNER AND PLACE OF PAYMENT. All payments hereunder
shall be payable in U.S. dollars. With respect to each Calendar Quarter, for
countries other than the United States, royalties shall first be calculated in
the currency of the country in which such royalties are earned and whenever
conversion of payments from any foreign currency shall be required, such
conversion shall be made in accordance with the internal, accounting principles
and practices of BMX and its applicable Affiliates as of the Effective Date, as
described in Exhibit C hereto. All payments due from BMX hereunder shall be made
by wire transfer of immediately available funds in U.S. Dollars to such bank
account in the United States as GP may from time to time designate.

      5.3 RECORDS AND AUDITS. BMX shall keep, and shall cause its Affiliates to
keep, for a period of not less than three (3) years after each Calendar Year,
complete, true and accurate books of account and other records containing all
information and data which may be necessary to ascertain and verify the amount
of royalties payable hereunder for such Calendar Year. During the Term of this
Agreement and for a period of three (3) years thereafter, GP shall have the
right from time to time (not to exceed twice during each Calendar Year) to
inspect, in confidence, and audit all such books and records of BMX. At its
option and expense, GP shall have the right to cause its independent public
accountants to conduct such review and audit. If any such audit results in a
determination that royalties payable for any Calendar Year have been underpaid
by five percent (5%) or more, BMX shall bear all costs of the inspection. In any
event, any royalty payment underpayment shall be paid within thirty (30) days
after the discovery of such underpayment, and, during the period from the
original date on which such amount should have been paid hereunder until the
date paid, shall bear interest at an annual rate of two percentage points above
the prime rate from time to time quoted by Bank of America at its principal
office in San Francisco, California, with changes in such prime rate to be
effective as of the date of each such change.

      5.4 WITHHOLDING OF TAXES. Any and all taxes imposed or levied on account
of royalties and revenue participation payments payable under this Agreement
which are required to be withheld by BMX or its Affiliates shall be withheld by
BMX and its Affiliates,

                                      -18-
<PAGE>
as the case may be, and shall be paid to the proper taxing authority. Proof of
payment reasonably satisfactory to GP shall be secured by BMX and submitted to
GP as evidence of such payment. Such taxes shall be deducted from the royalty or
revenue participation payment amounts that would otherwise be payable by BMX and
its Affiliates hereunder.

      5.5 NO ROYALTIES PAYABLE BY GP. All of the rights and licenses granted by
BMX to GP under this Agreement are royalty free, and nothing contained in this
Agreement obligates, or shall be deemed to obligate, GP to make any royalty
payments to BMX.

                                      -19-
<PAGE>
6. PRODUCT DEVELOPMENT

      Pursuant to the VIDAS Agreement, and prior to the Effective Date of this
Agreement, the Parties have been involved in collaborative efforts to jointly
develop assays for the VIDAS Instrumentation. Such collaborative efforts shall
be terminated in accordance with the following provisions:

      6.1 DEVELOPMENT TRANSITION. The Parties shall cooperate in the Development
Transition described herein and in the transfer of any information and Know-How
necessary for BMX to assume the development of the VIDAS Products. The parties
have agreed upon a work plan which will provide for the transition of product
development activities (hereafter the "Development Transition") from GP to BMX.
It is the Parties' intent that the Development Transition work plan, a copy of
which is attached as Exhibit D and incorporated herein by reference, shall
provide for the transfer from GP to BMX of any knowledge, records, procedures,
work instructions, formulations, and Know-How, necessary for the development of
the VIDAS Products or in carrying out the tasks as previously performed by GP
under the working relationship established between BMX and GP under the VIDAS
Agreement. Know-How and other information regarding such activities disclosed by
GP to BMX pursuant hereto may be used only in accordance with the rights granted
under this Agreement. It is the Parties' intent that the Development Transition
work plan shall also provide for the reasonable availability of GP personnel and
support by GP in the event needed to ensure compliance with regulatory
requirements or the orderly transfer of any development work to BMX, to the
extent that such support can only reasonably be provided by Gen-Probe within the
time-frame contemplated in the Development Transition work plan. Except as
otherwise stated herein, it is the Parties' intent that GP's obligations in
connection with the Development Transition shall terminate as of December 30,
2000 and the work plan shall reflect such termination date. Neither GP nor BMX
shall have any responsibility with respect to the development of the VIDAS
Products except as set forth in this Agreement and in the Development Transition
work plan. GP shall be compensated by BMX for GP's activities during the
Development Transition pursuant to the work plan, as set forth in Section 6.3,
below.

      6.2 COORDINATION OF DEVELOPMENT TRANSITION. The BMX-GP representatives
referred to under the VIDAS Agreement as the VIDAS Committee will serve to
coordinate the execution of the Development Transition work plan (and any
mutually-agreed modifications thereof). Both parties shall use commercially
reasonable and diligent efforts to perform their respective responsibilities
under the Development Transition work plan and this section and shall make
reasonably available any key personnel identified in the Development Transition
work plan to perform the work contemplated therein. During the Transition
Period, either Party shall have the right to propose modifications to the
Development Transition work plan by providing the other Party with a revised
work plan. The proposed modified work plan shall be subject to the other Party's
written approval. Within fifteen (15) days following the other Party's receipt
of any proposed modified work plan hereunder, that other Party shall either (i)
indicate its acceptance of the terms of such work plan by countersigning such
work plan and returning it to the proposing Party or (ii) communicate to the
proposing Party in writing any good faith objections to the terms of such Work
Plan, in which case the Parties shall discuss in good faith appropriate
revisions

                                      -20-
<PAGE>
to the work plan. Consent to a proposed modification of a work plan shall not be
withheld if that modification is consistent with the original intent of this
Agreement as stated in Section 6.1. Except as set forth in the preceding
sentence, nothing contained in this Section 6.2 shall impose any obligation on
either party to agree to any modification of the initial Development Transition
work plan. Upon execution by both Parties, a modified work plan shall be deemed
incorporated into and become a part of this Agreement.

      6.3 COMPENSATION OF GP. GP shall commit the number(s) of appropriately
qualified FTEs to the performance of GP's responsibilities under the Development
Transition work plan. In return for the obligations of GP pursuant to the VIDAS
Agreement and/or the Development Transition, GP shall be compensated for any and
all work performed by GP after December 31, 1999 at the rate of [***] per FTE.

      6.4 REPORTS. GP shall provide BMX with monthly written reports during the
Transition Period presenting a meaningful summary of GP's progress under the
Development Transition work plan. In addition, on reasonable request by BMX, GP
will make presentations of its activities under the Development Transition work
plan to inform BMX of the details of the work done under this Agreement.
Know-How and other information regarding such activities disclosed by GP to BMX
pursuant hereto may be used only in accordance with the rights granted under
this Agreement. GP will also make available to BMX such information of materials
concerning the VIDAS Products as may be reasonably requested by BMX for use in
seeking FDA and other regulatory approval of the VIDAS Products, or to otherwise
comply with regulatory requirements and such obligation shall survive the
termination of the Development Transition.

      6.5 VIDAS INITIAL PRODUCTS. After the Effective Date of this Agreement, GP
and BMX shall cooperate in the conclusion of development work for the VIDAS
Initial Products according to the Development Transition work plan and shall
also participate in product development as follows:

            (a) GP shall be responsible for the costs of clinical trials for
      VIDAS Initial Products only as set forth below:

                  (i)     GP shall be responsible for [***] of any Clinical
                          Trial Costs for the VIDAS Probe CT and VIDAS Probe GC
                          products; provided, however, that in no case shall
                          GP's liability hereunder exceed [***], total, for both
                          assays.

                  (ii)    GP shall be responsible for [***] of any Clinical
                          Trial Costs for the VIDAS CT/GC Screen product ;
                          provided, however, that in no case shall GP's
                          liability hereunder exceed [***].

                  (iii)   GP shall be responsible for [***] of any Clinical
                          Trial Costs for the VIDAS Probe MTB product; provided,
                          however, that in no case shall GP's liability
                          hereunder exceed [***].

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -21-
<PAGE>
                  (iv)    BMX shall invoice GP for Clinical Trial Costs on a
                          quarterly basis within thirty (30) days of the end of
                          the Calendar Quarter in which such Clinical Trial
                          Costs were incurred. Each such invoice shall itemize
                          Clinical Trials Costs in sufficient detail to inform
                          GP of the nature of such costs. Payment shall be made
                          by GP within thirty (30) days of its receipt of each
                          invoice.

                  (v)     BMX shall be responsible for overseeing the conduct of
                          all clinical trials contemplated by this Section. BMX
                          shall provide GP with quarterly written reports
                          describing in reasonable detail the progress and
                          results of each such trial and shall promptly respond
                          to GP's reasonable oral or written requests for
                          additional information regarding such clinical trials.

                  (vi)    BMX shall keep, and shall cause its Affiliates to
                          keep, for a period of not less than three (3) years
                          after the end of any clinical trial, complete, true
                          and accurate books of account and other records
                          containing all information and data which may be
                          necessary to ascertain and verify the amount of
                          Clinical Trial Costs payable hereunder. GP shall have
                          the right from time to time (not to exceed twice
                          during each Calendar Year) to inspect, in confidence,
                          and audit all such books and records of BMX. In the
                          event GP has overpaid any Clinical Trial Costs, BMX
                          shall refund to GP any Clinical Trial Cost overpayment
                          within thirty (30) days after the discovery of such
                          overpayment.

                  (vii)   GP and BMX shall have equal access rights to data and
                          information obtained from or in connection with the
                          clinical trials referred to above. GP and BMX
                          acknowledge the other Party's interest in publishing,
                          in oral or written form, information obtained from or
                          in connection with such clinical trials. Each Party
                          also recognizes the other Party's interest in
                          preserving the confidentiality of certain information.
                          Therefore, each party's right to publish information
                          obtained from or in connection with such clinical
                          trials shall be governed by Section 12.3(b). Nothing
                          contained herein shall limit BMX's sole right to
                          control the submissions to regulatory authorities for
                          the purpose of seeking approval of the VIDAS Products.

            (b) BMX shall use reasonable commercial efforts to complete
      development (including seeking regulatory approval) of the VIDAS Probe CT
      for the detection of Chlamydia trachomatis, the VIDAS Probe GC for the
      detection of Neisseria gonorrhoeae, and the VIDAS Probe MTB for the
      detection of Mycobacterium tuberculosis. In the event circumstances not
      contemplated in the Development Transition work plan arise, GP shall use
      Commercially Reasonable Efforts to assist BMX in completing development
      (including filings for regulatory approval) of such VIDAS Products and GP
      shall be compensated by BMX for any such efforts pursuant to Section 6.3,
      above.

                                      -22-
<PAGE>
      6.6 VIDAS QHIV PRODUCT. After the Effective Date of this Agreement, GP
shall cooperate with BMX in the transfer of development work for the VIDAS QHIV
Product according to the Development Transition work plan. GP shall not any have
responsibility or obligation in connection with the development of such products
except as set forth in the Development Transition work plan; provided, however,
that GP shall also be obligated to provide generic KBCs pursuant to section 6.11
for use in the development of such Products. GP shall not be obligated to
develop or provide any assay-specific KBC's for the VIDAS QHIV Product. Upon
request by BMX, GP shall use Commercially Reasonable Efforts to support BMX in
seeking regulatory approval for the VIDAS QHIV Product, to the extent that such
support can only reasonably be provided by GP (by way of example, and not by way
of limitation, by providing access to design history files reasonably related,
directly or indirectly, to the VIDAS QHIV Product), and GP shall be compensated
by BMX for any such efforts pursuant to Section 6.3, above.

      6.7 VIDAS HLA PRODUCT, VIDAS FOOD TESTING PRODUCTS, AND VIDAS FUTURE
INFECTIOUS DISEASE PRODUCTS. After the Effective Date of this Agreement, GP
shall not have any responsibility or obligation in connection with the
development of the VIDAS HLA Product, VIDAS Food Testing Products, or VIDAS
Future Infectious Disease Products except as set forth in the Development
Transition work plan; provided, however, that GP shall be obligated solely to
provide generic KBCs pursuant to section 6.11 for use in the development of such
Products. GP shall not be obligated to develop or provide any assay-specific
KBC's.

      6.8 VIDAS OTHER FUTURE PRODUCTS. BMX shall have the right to designate not
more than five (5) of the Assay targets set forth on Exhibit B attached hereto
as Option Targets hereunder for the development of VIDAS Other Future Products
in the VIDAS Field for use on VIDAS Instrumentation. BMX shall exercise its
right to designate Option Target(s) by providing GP (consistent with the license
granted pursuant to Article 2 above) with written notice of such designation(s).
All development work for such VIDAS Future Products shall be the sole
responsibility of BMX. GP shall not any have responsibility or obligation in
connection with the development of such Products except as expressly set forth
in the Development Transition work plan.

            (a) BMX shall exercise its right to designate VIDAS Other Future
      Products by selecting at least one VIDAS Other Future Product from the
      list of Option Targets during each Calendar Year beginning in 2001. If BMX
      fails to designate at least one VIDAS Other Future Product from the list
      of Option Targets by December 31 of any given Calendar Year, then GP shall
      have the right to strike one Option Target, from the list of those Option
      Targets remaining available for subsequent Calendar Years.

            (b) BMX's rights as to any VIDAS Other Future Product designated by
      BMX will expire one year after the date of BMX's selection of that VIDAS
      Other Future Product, unless BMX has by that date initiated development of
      that VIDAS Other Future Product, as evidenced by BMX having incurred
      financially-material costs for such development.

            (c) BMX's rights as to any particular VIDAS Other Future Product
      designated by BMX from the list of Option Targets will expire five years
      after the

                                      -23-
<PAGE>
      date of BMX's selection of that VIDAS Other Future Product, unless (i) the
      First Commercial Sale of such VIDAS Other Future Product occurs within
      such five year period or (ii) BMX demonstrates that it has consistently
      exercised reasonable diligence in connection with the development and
      commercial sale of such VIDAS Other Future Product, in which event the
      period pursuant to the preceding clause (i) shall be extended, once only,
      for an additional two years.

      6.9 ADDITIONAL VIDAS PROBE ASSAYS. BMX shall have the right to propose the
development of additional VIDAS Probe Assays (in addition to the VIDAS Products
as defined herein) and the extension of the licenses granted herein for such
assays. Thereafter the Parties shall commence discussions about the BMX
proposal, but Gen- Probe shall not have a binding obligation to grant any
licenses to BMX for additional VIDAS Probe Assays.

      6.10 DEVELOPMENT TRANSITION PERIOD. The Development Transition shall be
deemed to have commenced as of January 1, 2000 and shall be completed by
December 30, 2000 (the "Transition Period") . If GP has failed, solely due to
its own fault, to accomplish any action required by the initial work plan
referred to above, the Transition Period shall be extended until such action has
been accomplished by GP. After the Transition Period, all development work for
the VIDAS Products shall be the sole responsibility of BMX (except for the
financial obligations of GP with respect to the clinical trials described in
Section 6.5(a)). After the termination of the Transition Period and until
December 31, 2001, BMX may request that GP perform additional work in connection
with the development of the VIDAS Products, which work shall be limited in scope
to specific "troubleshooting"-type assignments. GP will promptly thereafter
inform BMX whether it has resources reasonably available for the proposed work
and, if so, GP will provide a quote for the charges which would be incurred by
BMX (which shall not be limited to the FTE charges otherwise set forth in this
Article.)

      6.11 MILESTONE PAYMENT UPON COMPLETION OF DEVELOPMENT TRANSITION PERIOD.
Upon the completion of the Development Transition in accordance with the
operative mutually-agree work plan, BMX shall make a milestone payment to GP. GP
agrees to accept, as and for this milestone payment, a payment equal in amount
to the sum paid to GP by BMX under the VIDAS Agreement and characterized
thereunder as prepaid royalties. Therefore, upon the completion of the
Development Transition in accordance with the operative mutually-agree work
plan, all of BMX's right and interest in the prepaid royalties shall be waived,
and BMX's prior payment to GP shall not be credited against any royalty payment
due from BMX to GP on any VIDAS Product pursuant to this Agreement.

      6.12 SUPPLY OF KEY BIOCHEMISTRY COMPONENTS FOR DEVELOPMENT WORK. Pursuant
to the provisions of Article 8, GP shall supply to BMX Key Biochemistry
Components which are not product-specific (e.g., "generic") and which GP has
developed prior to December 30, 2000, in order to facilitate BMX's development
of the VIDAS Products.

                                     -24-
<PAGE>
7. INTELLECTUAL PROPERTY

      7.1 VIDAS AGREEMENT. The classification of any invention conceived prior
to the Effective Date, and ownership thereof, shall be determined in accordance
with the categories and other terms and provisions of the VIDAS Agreement. To
the extent that any invention (including a Joint Collaboration Technology
invention) is subject to the terms of the VIDAS Agreement and categorized
thereunder, such invention shall become, as of the Effective Date, subject to
the provisions of this Agreement. If any invention is ever categorized by the
Parties as Joint Collaboration Technology under the VIDAS Agreement, that
categorization shall always apply thereafter for purposes of the Parties' access
to and use of and such technology under this Agreement, notwithstanding any
subsequent change to such categorization for other purposes.

      7.2 OWNERSHIP OF INVENTIONS. Ownership of any inventions (whether or not
patentable) that are first conceived after the Effective Date, including,
without limitation, any improvements to BMX Technology or GP Technology, shall
be determined in accordance with United States laws of inventorship (including,
where applicable, laws concerning contractual modification of the standard rules
of inventorship).

      7.3 DERIVATIVE INVENTIONS. The parties acknowledge and agree that,
notwithstanding that only limited rights have been granted hereunder, certain
new technology may be discovered, invented or created solely by BMX through
BMX's use of the GP Technology within the uses and in the manner contemplated by
this Agreement. The Parties also acknowledge and agree that, notwithstanding
that only limited rights have been granted hereunder, certain new technology may
be discovered, invented or created solely by GP through GP's use of the BMX
Technology within the uses and in the manner contemplated by this Agreement. Any
discovery or invention that is made by one Party as a result of access to the
other Party's Confidential Information, or through the use of, the other Party's
Technology as licensed under the VIDAS Agreement or this Agreement, and which is
closely and fundamentally related to such other Party's Technology, shall be
referred to herein as a "Derivative Invention". A Party which makes a Derivative
Invention shall be referred to for purposes of this Section 7.2 as an "Inventing
Party."

            (a) When an Inventing Party recognizes that it has made a Derivative
      Invention subject to this Section 7.3, it shall promptly disclose that
      fact to the other Party.

            (b) Any Derivative Invention shall be considered to be within the
      Technology of the Inventing Party and to be included within the license
      grants of the Inventing Party to the other Party under this Agreement.

            (c) The Inventing Party may use such Derivative Invention, together
      with the other Party's Technology licensed hereunder, for those uses and
      purposes which do not require any further license of the Technology of the
      other Party other than that granted herein (it being the agreement of the
      Parties that there are no implied license rights created by this
      Agreement).

                                      -25-
<PAGE>
            (d) Each Inventing Party agrees not to assert its rights in a
      Derivative Invention in such a manner as would block or diminish the other
      Party's rights to practice, independently of the Derivative Invention
      itself, the technology of such other Party directly related to the
      technology with which the Derivative Invention was made.

            (e) Upon request, the Inventing Party shall grant a nonexclusive
      license to the other Party to enable such other Party to make, use, sell,
      offer for sale, and import products which use or include the Derivative
      Invention. If a Derivative Invention is not separately patentable, or if
      the Derivative Invention does not have any substantial commercial use
      other than uses which would infringe the Technology of the other Party
      which is the subject of this Agreement, then the nonexclusive license to
      be granted hereunder shall be royalty-free. If a Derivative Invention is
      patentable and has a substantial commercial use which would not infringe
      the Technology of the other Party, then the nonexclusive license to be
      granted hereunder shall include commercially reasonable terms to be
      negotiated. The "commercially reasonable terms" referred to above shall
      give full recognition, in favor of the other Party, to the value of the
      Technology of such other Party with which the Derivative Invention was
      made. The commercially reasonable terms" shall also give full recognition,
      in favor of the Inventing Party, to the value of the inventive application
      of such Technology. Nothing contained herein shall require the Inventing
      Party to license to the other Party any technology other than the
      Derivative Invention itself.

      7.4 OWNERSHIP OF BMX TECHNOLOGY. Subject to the grant of intellectual
property rights to GP under the licenses granted under Article 3, BMX shall own
all rights to the BMX Technology. The filing, prosecution and maintenance of
patent rights and other proprietary rights directed at the protection of all
rights to the BMX Technology shall be the responsibility of, and at the
discretion of, BMX.

      7.5 OWNERSHIP OF GP TECHNOLOGY. Subject to the grant of intellectual
property rights to BMX under the licenses granted under Article 3, GP shall own
all rights to the GP Technology. The filing, prosecution and maintenance of
patent rights and other proprietary rights directed at the protection of all
rights to the GP Technology shall be the responsibility of, and at the
discretion of, GP.

      7.6 NO RESTRICTION ON USE OF TECHNOLOGY. Subject to the licenses granted
under Article 3, neither BMX nor GP shall be restricted from using, or
authorizing the use of, its own technology (including technology which
constituted such Party's Core-Related Collaboration Technology or Collaboration
Technology, or constituted Joint Collaboration Technology, under the VIDAS
Agreement) whether in the Field or outside the Field (or any portion thereof).
Without limiting the foregoing or any other provision of this Agreement, each
Party hereby agrees that this Section supersedes Sections 4.9, 4.10 and 4.11(d)
of each of the VIDAS Agreement in their entirety.

                                      -26-
<PAGE>
      7.7 PATENT PROSECUTION OF INVENTIONS.

            (a) SOLELY-OWNED INVENTIONS. Subject to the terms of the Invention
      Classification Agreement executed by the Parties concurrently with this
      Agreement, BMX shall be responsible for the filing, prosecution and
      maintenance of all patents claiming BMX Technology and all patent
      applications and patents covering any BMX Derivative Inventions at BMX's
      sole expense. Subject to the terms of the Invention Classification
      Agreement executed by the Parties concurrently with this Agreement, GP
      shall be responsible for the filing, prosecution and maintenance of all
      patents claiming GP Technology and all patent applications and patents
      covering any GP Derivative Inventions at GP's sole expense. The inventing
      Party shall keep the other Party informed of progress with regard to the
      filing, prosecution, maintenance, enforcement and defense of patents
      applications and patents claiming any Derivative Invention. No Party shall
      include any Confidential Information of the other Party in any patent
      application without the express written consent of the other Party.

            (b) JOINT INVENTIONS. Subject to the terms of the Invention
      Classification Agreement executed by the Parties concurrently with this
      Agreement, the Parties shall negotiate reasonably and in good faith with
      respect to preparing, filing and prosecuting any patent applications or
      other appropriate filings with respect any invention that is owned jointly
      by the Parties and maintaining any patents, copyrights or other similar
      rights issued thereon, using patent counsel reasonably acceptable to the
      other Party. The Parties may select one Party to be responsible for such
      activities with respect to any specific invention and may allocate between
      them the out-of-pocket expenses for patent preparation, filing,
      prosecution and maintenance. If the responsible Party with respect to any
      joint invention decides to abandon or not to pursue prosecution of any
      patent right which claims such joint invention, it shall give prior notice
      to other Party and permit the other Party, at its option and expense, to
      undertake such obligations. Each Party shall fully cooperate with the
      other Party in connection with any joint invention.

      8. INFRINGEMENT BY THIRD PARTIES.

            (a) Each Party shall notify the other of any suit which such Party
      proposes to commence with respect to any jointly-owned patent. The Party
      proposing to commence suit shall give the other Party reasonable advance
      notice of its intention to commence such suit, the reasons for commencing
      such suit and the evidence supporting its claims, and a reasonable
      opportunity to make comments and suggestions regarding the advisability of
      commencing such suit and the litigation strategies therefor. Subject to
      confidentiality requirements as may be reasonably necessary to maintain
      privilege or fulfill obligations imposed by Third Party agreements or
      court order, the Party bringing the suit shall keep the other Party
      promptly informed, and shall consult with the other Party on a periodic
      basis and provide the other Party with copies of all court filings made in
      such suit, including all pleadings and other assertions therein. The Party
      bringing suit shall select counsel reasonably acceptable to the other
      Party. Except as otherwise provided in this Agreement, the Party bringing
      suit shall pay all expenses of the suit, including

                                      -27-
<PAGE>
      without limitation attorneys' fees and court costs, and shall be entitled
      to all damages, royalties, awards, judgments, settlement amounts, costs or
      other payments recovered in such suit.

            (b) In the event a Party brings a suit relating to jointly-owned
      patents, the other Party, at its sole discretion, may elect within sixty
      (60) days after the commencement of such suit, to contribute a fixed
      percentage of up to fifty (50%) of the costs incurred by the suing Party
      in connection with such suit. In the event of any such election, all
      damages, royalties, awards, judgments, settlement amounts, costs or other
      payments recovered in such suit shall be shared by the Parties on a pro
      rata basis in accordance with their respective cost contributions.

            (c) In the event a Party brings a suit relating to jointly-owned
      patents and the other Party does not voluntarily elect to participate in
      such suit pursuant to subparagraph (b) above or otherwise, such other
      Party shall, upon request, reasonably cooperate with the Party bringing
      suit by providing any documents or information relevant to the suit. The
      Party bringing suit shall ensure that the confidential information of the
      other Party provided pursuant to this section shall be adequately
      protected and, upon request, shall reasonably compensate the other Party
      for its efforts in cooperating in the manner described herein.

                                      -28-
<PAGE>
      7.9 INFRINGEMENT OF THIRD PARTY RIGHTS.

            (a) In the event that any Third Party makes a written claim or
      demand, or brings an action, suit or proceeding, against either Party (or
      any of its Affiliates), alleging infringement, unauthorized use or
      misappropriation of such Third Party's Technology or Confidential
      Information, arising out of, in connection with or relating to any VIDAS
      Products or any of the activities of the Parties directly related to this
      Agreement, such Party shall promptly notify the other Party in writing,
      and provide copies of all materials or papers received by or served on
      such Party from or by such Third Party. Each Party agrees to make
      available to the other Party, without charge, its advice and assessment
      with respect to the technical merits of any matter which is the subject of
      any such claim, demand, action, suit or proceeding.

            (b) It is the intention of the Parties that the Party against whom
      such action is brought shall assume the defense of such action; provided,
      however, that such Party shall keep the other Party reasonably informed of
      developments in such action. Notwithstanding the foregoing, if both
      Parties are named as defendants in such action, the Parties shall jointly
      assume the defense of such action. To the extent that GP incurs any costs
      or suffers any damages or awards in connection with any such action, BMX
      shall be obligated to contribute thereto to the extent provided in Section
      7.10 below.

            (c) Notwithstanding anything to the contrary in the foregoing, if
      any such action involves claims which in any way challenge or call into
      question the Technology of either Party, such Party shall have the right
      to review and approve all assertions regarding the construction, scope or
      validity of Patent claims included in the relevant Technology and in doing
      so shall act reasonably and in good faith in defense of such Technology.
      All such assertions shall be submitted to such Party for its review and
      approval before being presented by the other Party in any such action by
      way of pleading, oral argument or otherwise.

      7.10 BMX CONTRIBUTION OBLIGATIONS.

            (a) Subject to the amount limitations set forth in Section 7.10(b)
      below, BMX shall contribute to and reimburse GP, upon GP's request, for
      [***] of all costs and expenses, (such costs and expenses to include,
      without limitation, reasonable attorneys' fees and any reasonable lump sum
      cash amount paid by GP upon settlement of litigation prior to and in lieu
      of any verdict or award of damages (but not any verdict or award of
      damages nor any payment upon any compromise of any verdict or award nor
      any payments in kind or assumption of obligations upon settlement),
      incurred by GP in (i) defending against any pending or future claims,
      suits, actions, proceedings or arbitrations which in any way challenge or
      call into question the validity of any patent within the GP Core
      Technology (as defined in the VIDAS Agreement), (ii) enforcing rights in
      an action commenced under Section 7.8 or (iii) defending against claims
      under Section 7.9; provided, however, that BMX shall have the right to
      elect not to pay its share of the aforesaid costs and expenses for any
      Technology which is not then being used by BMX in the VIDAS
      Instrumentation or any VIDAS Product and which is not

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -29-

<PAGE>
      considered by BMX to be of material importance to BMX. If BMX makes the
      election set forth in the preceding sentence, it shall forthwith lose all
      license rights granted to it hereunder with respect to such Technology.
      The Parties agree that BMX's obligations under this paragraph (a) shall
      remain in force during all periods in which any GP Core Technology (as
      defined in the VIDAS Agreement) is being exploited by BMX or its
      Affiliates under the licenses granted hereby. The obligation of BMX to
      reimburse GP for its expenses hereunder shall be separate and distinct
      from, and cumulative to, any obligation of BMX under any other agreement
      (including the ANAIS Agreement and any amendment thereto). Notwithstanding
      any other provision of this Section 7.10(a), the obligation of BMX under
      the VIDAS Agreement, the ANAIS Agreement, and any amendments thereto,
      combined, in connection claims asserted against GP by Enzo Biochem, Inc.
      in the lawsuit entitled Enzo Biochem, Inc. v. Gen-Probe Incorporated, case
      no. 99 Civ. 4548 (AKH), United States District Court for the Southern
      District of New York, shall be [***] of all costs and expenses incurred by
      GP before or after the Effective Date. For the avoidance of doubt,
      Sections 7.10(b) through (e) shall apply to the reimbursement obligation
      for the Enzo litigation.

            (b) The maximum combined aggregate amount of any contribution and
      reimbursement paid by BMX to GP in any one Calendar Year under this
      Section 7.9 and the VIDAS Agreement, the ANAIS Agreement, and any
      amendment to the ANAIS Agreement, combined, shall not exceed [***] and the
      total maximum combined aggregate amount of all such reimbursements by BMX
      to GP under this Section 7.10 shall not exceed [***] (which maximum amount
      shall include all contributions previously made by BMX to GP under the
      VIDAS Agreement and ANAIS Agreement); provided, however, that GP shall
      have used under the VIDAS Agreement and shall use under this Agreement
      reasonable efforts to obtain similar reimbursement and contribution
      commitments in any other agreements licensing GP Technology and, to the
      extent that GP has been or is able in the future to obtain similar burden
      sharing from any other Party, then BMX's share and respective maximum will
      be reduced in proportion to the share and the respective maximum of the
      burden assumed by such other Party or Parties, in such manner that any
      such contributions actually required to be made by any such licensees of
      GP in any Calendar Year shall reduce BMX's obligation under this Section
      7.10 with respect to such Calendar Year on a dollar for dollar basis for
      such Calendar Year and shall reduce the total maximum aggregate amount of
      BMX's financial commitment under this Section 7.10 on a dollar for dollar
      basis during the Term of this Agreement. Any costs and expenses incurred
      by GP which are not subject to reimbursement by BMX in a particular year
      due to BMX having previously paid the annual limit of [***] for that year
      may be carried over into the following year by GP and reimbursement may be
      sought by GP in the following year (subject to the continuing annual and
      cumulative maximum limits); provided, however, that in no event shall any
      expense be carried over into any calendar year which begins more than one
      year after the termination of the litigation which gave rise to the
      expense.

            (c) In the event any damages, awards or other amounts are received
      by or awarded to GP in connection with any action or proceeding in which
      BMX has

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -30-
<PAGE>
      contributed to GP's costs under this Section 7.10, BMX shall be entitled
      to receive a proportionate share thereof based upon the percentage of
      costs reimbursed by it in connection with such action.

            (d) Within sixty (60) days after the end of each Calendar Quarter,
      GP shall submit to BMX a statement of the contribution and reimbursement
      amount payable by BMX to GP under this Section 7.10 for such Calendar
      Quarter, with appropriate supporting documentation. Subject to reasonable
      requests for backup detail, BMX shall pay the contribution and
      reimbursement amount to GP within thirty (30) days after receiving such
      statement from BMX. Interest shall accrue and be payable on all amounts
      which are not timely paid at the prime rate referred to in Section 5.3
      above.

            (e) With respect to any litigation subject to BMX's contribution
      obligation, BMX shall have the same rights to be informed by and consult
      with GP and to receive copies of all court filings as was provided in the
      VIDAS Agreement and BMX's contribution obligation hereunder shall be
      conditional on GP's fulfillment on a timely and ongoing basis of such
      future obligations hereunder.

                                      -31-
<PAGE>
8. MANUFACTURING AND SUPPLY OBLIGATIONS

      GP shall supply to BMX the Key Biochemistry Components ("KBCs") to be
incorporated into VIDAS Products on the terms set forth below. Nothing contained
in this Article 8 shall be deemed to constitute a requirements contract.

      8.1 KEY BIOCHEMISTRY COMPONENTS.

            (a) During the period from the Effective Date to January 1, 2003, or
      for any extended period pursuant to section 8.2(c), those KBCs to be
      incorporated into VIDAS Products which GP has developed prior to the
      Effective Date shall be manufactured by GP in accordance with terms of
      this Agreement, except as otherwise provided herein or agreed by the
      Parties. All Key Biochemistry Components manufactured by GP hereunder
      shall be transferred and sold to BMX in accordance with the standard GP
      purchase order form attached as Exhibit E hereto, subject to the
      warranties, exclusions and limitations set forth therein. GP's right and
      obligation to manufacture shall be limited to (1) those KBCs to be
      incorporated into the VIDAS Initial Products which GP has developed prior
      to December 30, 2000 and (2) those non-product specific (e.g., "generic")
      KBCs which GP has developed prior to December 30, 2000 and which are to be
      incorporated into, or used for development of, VIDAS Products.

            (b) All KBCs manufactured hereunder, other than those referred to in
      subparagraph (c) below, shall be sold to BMX at [***] of GP's
      Fully-Absorbed Manufacturing Cost, plus (i) an incremental amount (the
      "Margin") equal to [***] of GP's Fully Absorbed Manufacturing Cost and
      (ii) shipping, handling and related costs associated with the delivery of
      KBCs to BMX; provided, however, that in no case shall the Margin with
      respect to all KBC's in a product exceed a ceiling amount of [***] of the
      Net Sales price per unit of the VIDAS Product into which such KBCs are to
      be incorporated except that in no case shall the Margin be less than a
      floor amount of [***] of such Manufacturing Cost. Repayment of any excess
      payment to GP shall be offset from any royalty payments (with appropriate
      disclosure in the quarterly reports described in Section 5.1) or otherwise
      reimbursed to BMX in such manner as the Parties may agree.

            (c) All Key Biochemistry Components manufactured hereunder which BMX
      specifically designates for product development purposes (and which are in
      fact used for development purposes) shall be sold to BMX at [***] of GP's
      Fully-Absorbed Manufacturing Cost, plus (i) shipping, handling and related
      costs associated with the delivery of Key Biochemistry Components to BMX
      and (ii) an incremental amount (the "Margin") equal to [***] of GP's Fully
      Absorbed Manufacturing Cost, except that such Manufacturing Costs shall
      not include any costs which BMX has funded by paying GP's FTE cost
      pursuant to an approved work plan adopted in accordance with Article 8.
      Upon request by GP, BMX shall provide reasonable evidence that KBCs
      designated for product development purposes were used for such purposes.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
                                      -32-
<PAGE>
            (d) Attached hereto as Exhibit F are GP's estimates as of the
      Effective Date of GP's Fully-Absorbed Manufacturing Cost for the KBCs of
      each of the Initial VIDAS Products. GP shall use its best efforts to
      provide BMX with updated estimates of such Fully-Absorbed Manufacturing
      Cost on at least an annual basis. To the extent that GP incorporates
      efficiencies into the manufacturing of KBCs to be sold to BMX hereunder,
      GP agrees to pass on any concomitant cost savings to BMX.

            (e) GP shall keep, and shall cause its Affiliates to keep, for a
      period of not less than three (3) years after each Calendar Year,
      complete, true and accurate books of account and other records containing
      all information and data which may be necessary to ascertain and verify
      GP's Fully-Absorbed Manufacturing Cost of KBCs during such Calendar Year
      or any part thereof. During the Term of this Agreement and for a period of
      three (3) years thereafter, BMX shall have the right from time to time
      (not to exceed twice during each Calendar Year) to inspect, in confidence,
      and audit all such books and records of GP. GP shall refund to BMX any
      overpayment for KBCs within thirty (30) days after the discovery of such
      overpayment.

            (f) Not less than three (3) months prior to the First Commercial
      Sale of any VIDAS Product and, thereafter, not less than three (3) months
      prior to the commencement of each Calendar Year during which BMX
      reasonably anticipates that GP will manufacture KBCs pursuant to this
      Agreement, BMX shall provide GP with a reasonable forecast of its
      projected requirements for Key Biochemistry Components during the next
      Calendar Year, broken down by Calendar Quarter. BMX shall update such
      annual forecast, for a rolling twelve month period, as frequently as
      practicable but in any event not less frequently than quarterly. BMX shall
      submit written purchase orders to GP for Key Biochemistry Components at
      least sixty (60) days prior to the requested delivery date therefor, which
      shall be for not less than [***] of the most recent quarterly forecast. GP
      shall promptly confirm receipt of such purchase orders from BMX. If BMX
      submits orders during any Calendar Quarter which exceed BMX's most recent
      quarterly forecast for such quarter by more than [***], GP shall have the
      right to defer delivery of any such excess orders until the next Calendar
      Quarter. Subject to the foregoing and the remaining provisions of this
      Article 8, GP will produce and ship to BMX, and BMX shall purchase, all of
      such confirmed purchase order amounts.

            (g) GP shall invoice BMX for KBCs delivered under this section upon
      shipment of each order. Payment shall be made by BMX within thirty (30)
      days of its receipt of each invoice.

            (h) The Parties shall consult regularly as to the manner of
      performance hereunder and to assure reliability and continuity of KBCs. If
      at any time either Party is reasonably of the view that GP may not be able
      to meet future purchase orders from BMX, such Party shall notify the other
      Party in writing and the Parties shall in good faith cooperate and
      endeavor to make appropriate arrangements for a continuous and adequate
      supply of KBCs to BMX. In the event that GP becomes aware of any
      occurrences or developments that could reasonably be anticipated to

      *** Certain information on this page has been omitted and filed separately
      with the Commission. Confidential treatment has been requested with
      respect to the omitted portions.

                                      -33-
<PAGE>
      create problems or impediments to supply KBCs to BMX, or to interrupt
      supply of such KBCs, GP shall give BMX reasonable advance notice thereof
      and the Parties shall consult as to the resolution of the matter.

            (i) In the event that GP fails to supply BMX, for any reason other
      than an event of Force Majeure, with at least [***] of any KBC on the
      delivery date set forth in a confirmed purchase order pursuant to
      subsection (f) above for any three months in any nine-month period, or,
      after receipt of a valid purchase order GP fails to supply at least [***]
      of BMX's purchase order for any KBC within thirty days after the requested
      delivery date for such KBC, then BMX shall have the right, after
      consultation with Gen-Probe and at BMX's option, to either: (i) procure
      any such KBC from alternative sources or (ii) manufacture, or have
      manufactured, BMX's requirements for such KBC to be incorporated into the
      VIDAS Products. In the event BMX so elects to manufacture, GP use its best
      efforts to provide BMX with reasonable assistance to enable BMX to
      manufacture such KBC. Such assistance shall include, but not be limited to
      delivering to BMX any necessary records, procedures, work instructions,
      formulations, raw materials and personnel support to allow BMX to
      manufacture such KBC to be incorporated into the VIDAS Products. BMX's
      rights under this paragraph with respect to any failure by GP to supply
      BMX shall be BMX's sole and exclusive remedy.

            (j) GP shall promptly notify BMX in the event it is considering
      implementing any material changes to the KBC's or to their manufacturing
      processes and shall not undertake any such changes without BMX's prior
      written approval, which shall not be unreasonably withheld. GP shall
      provide BMX with any records and information that may be necessary in
      order for BMX to review any proposed change. In the event BMX reasonably
      withholds consent to any change proposed by GP, then GP shall continue to
      supply BMX with the KBC in question as originally specified, unless such
      supply is impossible or impracticable due to the unavailability of key raw
      materials or regulatory restrictions, in which case the Parties agree to
      make a good faith effort to implement a mutually satisfactory alternative
      (e.g. purchase of large stock of raw material or finished KBC). In the
      event GP implements a change to a KBC or its manufacturing processes with
      the approval of BMX, which change requires a regulatory submission, GP
      shall at the request of BMX continue to supply BMX with such original KBC
      until such time as BMX receives approval of the regulatory agency for such
      changed material.

            (k) Notwithstanding the foregoing, in the event BMX, due to a lot
      loss or other unforeseeable event, determines that it is suffering a
      shortage, or will suffer a shortage, of any KBC(s), BMX shall provide GP
      with written notice of such shortage together with a firm order for the
      amount of such KBC as BMX needs to eliminate the shortage. GP shall upon
      such notice use Commercially Reasonable Efforts to fill all of BMX's order
      for such KBC on an expedited basis (regardless of the forecasted amount
      for such KBC).

      8.2 TRANSITION OF MANUFACTURING CAPABILITY. GP and BMX agree that
responsibility for manufacturing KBCs shall be transferred to BMX as follows:

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -34-
<PAGE>
            (a) Following the Effective Date, the Parties shall develop and
      agree upon a work plan which will provide for completion of the transfer
      of KBC manufacturing know-how from GP to BMX in order to allow the orderly
      transfer of manufacturing responsibility for all KBC's to BMX on or before
      January 1, 2003, giving due consideration to the need for any required
      regulatory approval(s), including all procedures, work instructions,
      formulations, and necessary and unique materials necessary for such
      manufacturing. The work plan shall provide for access to any needed
      suppliers of KBC's or sub-components and shall seek to obtain for BMX
      similar terms to existing GP terms for such materials from such suppliers.
      The work plan shall also provide for transfer of specifications and QC
      procedures as conveyed to suppliers or used internally at GP for final and
      in-process QC of KBC's or sub-components. The work plan shall also provide
      for the transfer of work-in- progress and raw materials and shall provide
      adequate time to allow the performance of any preparatory work, including
      procurement of plant and equipment, calibrations, validation studies and
      the running of test lots, that may be necessary before the actual
      manufacture of KBCs is performed by BMX. The work plan shall provide
      reasonable compensation to GP for the FTE's required for the transfer of
      manufacturing and for any raw materials and work-in-progress transferred.

            (b) In the event BMX provides written notice to GP prior to January
      1, 2003, that it is capable of manufacturing a particular KBC, GP shall be
      permitted, but shall not be required, to provide written notice to BMX
      that it will no longer manufacture and supply such KBC under this
      Agreement. Notwithstanding the foregoing, BMX shall be permitted to
      manufacture validation lots of KBCs and limited production lots (which
      shall not exceed [***] of BMX's forecasted need for the subsequent
      quarter) for purposes of ensuring BMX's ability to manufacture its
      requirements of KBCs at the end of the Transition Period.

            (c) GP and BMX shall each have the option, upon six months notice
      given after January 1, 2003, to elect and require that manufacturing of
      KBC's shall be transferred from GP to BMX after July 1, 2003. The six
      month period for transition shall be extended to the extent necessary for
      any required regulatory approval(s) which may be delayed, without fault of
      BMX, beyond such six-month period.

            (d) The parties shall reasonably cooperate in carrying out the work
      plan adopted pursuant to subparagraph (a). Upon the election of either
      Party to transfer manufacturing pursuant to this section, the Parties
      shall reasonably update the work plan and cooperate in completing the
      transfer of manufacturing know-how unique to the VIDAS Products and the
      transfer of raw materials and work-in-progress pursuant to the updated
      work plan.

            (e) EXCEPTIONS. Notwithstanding any other provision of this
      Agreement, unless GP fails to supply BMX (within the meaning of Section
      8.1(i)) with any item listed below G-P shall at all times have the
      exclusive right and obligation to make, or have made by a Third Party, the
      following items: [***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -35-
<PAGE>
      [***]. Notwithstanding any other provision of this Agreement, BMX shall at
      all times have the right to purchase such items from GP in reasonable
      commercial quantities to be used by BMX for the purposes of this
      Agreement.

                  (i)     Notwithstanding any other provision of this Agreement,
                          GP shall have no obligation to make any disclosure to
                          BMX concerning the manufacture of the above-listed
                          items unless GP fails to supply BMX with such item, as
                          set forth in Section 8.1 (i).

                  (ii)    Notwithstanding any other provision of this Agreement,
                          BMX shall at all times have the right to purchase any
                          or all of the above-listed items from a Third Party or
                          to manufacture such items itself; provided, however,
                          that nothing contained herein shall require GP to make
                          any disclosure of Confidential Information to BMX or
                          to such Third Party in connection with BMX's purchase
                          of such items from the Third Party. Notwithstanding
                          any other provision of this Agreement, BMX shall at
                          all times have the right to purchase, in reasonable
                          commercial quantities to be used by BMX for the
                          purposes of this Agreement, any or all of the above
                          items directly from any entity which supplies such
                          items to GP in the same form as purchased by GP;
                          provided, however, that nothing contained herein shall
                          require GP to make any disclosure of Confidential
                          Information to BMX, or require GP to permit such
                          disclosure to BMX by such Third Party, in connection
                          with BMX's purchase of such items from the Third
                          Party.

                  (iii)   Immediately following execution of this Agreement, GP
                          shall use its best efforts to arrange for a Third
                          Party supplier to manufacture [***] used by BMX in
                          accordance with the rights granted by this Agreement.
                          Upon completion of arrangements with a Third Party
                          supplier, any requests by BMX for [***] used in
                          accordance with the rights granted by this Agreement
                          shall be made to GP and GP shall direct such requests
                          to the Third Party supplier. BMX shall have the right
                          to disclose any Confidential Information concerning
                          such [***] only to the Third Party supplier and to
                          decline to disclose such Confidential Information to
                          GP.

                  (iv)    If GP makes improvements to any of the above-listed
                          items, it shall make such improvements reasonably
                          available to BMX pursuant to this Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -36-
<PAGE>
                  (v)     GP shall at all times after July 1, 2002 have the
                          right on written notice to BMX to require BMX to
                          assume responsibility for manufacturing any or all of
                          the items listed above. Promptly after GP delivers any
                          such notice, the Parties shall meet to agree,
                          reasonably and in good faith, upon a plan for
                          transition of manufacturing from GP to BMX. As part of
                          any such transition, GP shall make any and all
                          disclosures necessary to permit BMX to make or have
                          made such items.

                  (vi)    BMX shall not have any right to analyze, dissect, or
                          disassemble any such item which is not properly
                          available from sources other than GP in order to
                          circumvent the need to for BMX to acquire such item
                          from GP or GP's supplier.

      8.3  SAMPLE COLLECTION KITS.

            (a) During the term of this Agreement GP shall, on request of BMX,
      also manufacture and sell to BMX sample collection kits as more fully
      described in Exhibit G hereto ("Sample Collection Kits") in accordance
      with terms of this Agreement. All Sample Collection Kits manufactured by
      GP hereunder shall be transferred and sold to BMX in accordance with the
      standard GP purchase order form attached as Exhibit E hereto, subject to
      the warranties, exclusions and limitations set forth therein.

            (b) Sample Collection Kits manufactured hereunder shall initially be
      sold to BMX at a transfer price of [***], plus shipping, handling and
      related costs associated with the delivery of Sample Collection Kits to
      BMX. The transfer price of Sample Collection Kits will be reviewed
      annually and adjusted to reflect market pricing conditions and to ensure a
      minimum distribution margin for BMX of [***]; provided, however, that in
      no case shall the transfer price be less than [***] nor less than GP's
      Fully Absorbed Manufacturing Cost; and provided, further, that BMX shall
      not commercialize Sample Collection Kits as a loss leader product. The
      price of the Sample Collection Kits as set forth in this paragraph does
      not include the cost of the cap for the sample collection device, which GP
      shall sell to BMX at its cost [***].

            (c) Not less than three (3) months prior to the First Commercial
      Sale of any VIDAS Product and, thereafter, not less than three (3) months
      prior to the commencement of each Calendar Year during which BMX
      reasonably anticipates that GP will manufacture Sample Collection Kits
      pursuant to this Agreement, BMX shall provide GP with a reasonable
      forecast of its projected requirements for Sample Collection Kits during
      the next Calendar Year, broken down by Calendar Quarter. BMX shall update
      such annual forecast, for a rolling twelve month period, as frequently as
      practicable but in any event not less frequently than quarterly. BMX shall
      submit written purchase orders to GP for Sample Collection Kits at least
      sixty (60) days prior to the requested delivery date therefor, which shall
      be be for not less than [***] of the most recent quarterly forecast. If
      BMX submits

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -37-
<PAGE>
      orders during any Calendar Quarter which exceed BMX's most recent
      quarterly forecast for such quarter by more than [***], GP shall have the
      right to defer delivery of any such excess orders until the next Calendar
      Quarter. Subject to the foregoing and the remaining provisions of this
      Article 8, GP will produce and ship to BMX, and BMX shall purchase, all of
      such confirmed shipment order amounts.

            (d) GP shall invoice BMX for goods delivered under this Section 8.3
      upon shipment of each order. Payment shall be made by BMX within thirty
      (30) days of its receipt of each invoice.

            (e) The Parties shall consult regularly as to the manner of
      performance hereunder and to assure reliability and continuity of Sample
      Collection Kits. If at any time either Party is of the view that GP may
      not be able to meet future purchase orders from BMX, such Party shall
      notify the other Party in writing and the Parties shall in good faith
      cooperate and endeavor to make appropriate arrangements for a continuous
      and adequate supply of Sample Collection Kits to BMX. In the event that GP
      becomes aware of any occurrences or developments that could reasonably be
      anticipated to create problems or impediments to supply Sample Collection
      Kits to BMX, or to interrupt supply of such Sample Collection Kits, GP
      shall give BMX reasonable advance notice thereof and the Parties shall
      consult as to the resolution of the matter.

            (f) In the event that GP fails to supply BMX, for any reason other
      than an event of Force Majeure, with at least [***] of Sample Collection
      Kits on the delivery date set forth in a valid purchase order pursuant to
      subsection (c) above for any three months in any nine-month period, or,
      after receipt of a valid purchase order GP fails to supply at least [***]
      of BMX's purchase order for Sample Collection Kits within thirty days
      after the requested delivery date for such Sample Collection Kits, then
      BMX shall have the right, after consultation with Gen-Probe and at BMX's
      option, to either: (i) procure Sample Collection Kits from alternative
      sources or (ii) manufacture, or have manufactured, BMX's requirements for
      such Sample Collection Kits. In the event BMX so elects to manufacture, GP
      shall provide BMX with reasonable assistance to enable BMX to manufacture
      Sample Collection Kits. Such assistance shall include, but not be limited
      to delivering to BMX any necessary records, procedures, work instructions,
      formulations, raw materials and personnel support to allow BMX to
      manufacture Sample Collection Kits. Notwithstanding any other provision of
      this Agreement, GP shall have no obligation to make any disclosure to BMX
      concerning the manufacture of Sample Collection Kits unless G-P fails to
      supply BMX with such item.

            (g) GP shall promptly notify BMX in the event it is considering
      implementing any changes to the Sample Collection Kits or to their
      manufacturing processes and shall not undertake any such changes without
      BMX's prior written approval, which shall not be unreasonably withheld. GP
      shall provide BMX with any records and information that may be necessary
      in order for BMX to review any proposed change. In the event BMX
      reasonably withholds consent to any change proposed by GP, then GP shall
      continue to supply BMX with the Sample Collection

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -38-
<PAGE>
      Kit in question as originally specified, unless such supply is impossible
      or impracticable due to the unavailability of key raw materials or
      regulatory restrictions, in which case the Parties agree to make a good
      faith effort to implement a mutually satisfactory alternative. In the
      event GP implements a change to a Sample Collection Kit or its
      manufacturing processes with the approval of BMX, which change requires a
      regulatory submission, GP shall at the request of BMX continue to supply
      BMX with such original Sample Collection Kit until such time as BMX
      receives approval of the regulatory agency for such changed material.

      8.4  BMX MANUFACTURING RESPONSIBILITIES.

            (a) Unless otherwise agreed by BMX and except as otherwise expressly
      set forth herein, BMX shall be solely responsible for the manufacture,
      assembly, marketing, sale, and delivery of VIDAS Products and VIDAS
      Instrumentation.

            (b) BMX shall not grant or extend to customers any specific product
      warranties regarding Key Biochemistry Components manufactured by GP
      without GP's prior written consent.

      8.5  MANUFACTURING ACTIVITIES.

            (a) The Parties shall reasonably consult on all matters relating to
      the manufacture of the Key Biochemistry Components and Sample Collection
      Kits.

            (b) Manufacturing activities shall be conducted in compliance with
      all applicable legal and regulatory requirements in each relevant
      jurisdiction, including, without limitation, the requirements of the
      United States Food and Drug Administration (the "FDA"). GP shall perform
      all of its manufacturing obligations under this Agreement in accordance
      with all FDA requirements including the Quality Systems Regulations as set
      forth in 21 C.F.R. 820, "good laboratory practices," and "good clinical
      practices" to the extent applicable, and GP's own standard operating and
      quality control standards and applicable industry-wide standards for
      proper laboratory procedures and practices.

            (c) GP will allow BMX to audit GP's records and facilities used in
      the manufacture of KBCs and Sample Collection Kits at least once a year or
      more frequently if necessary. GP agrees to respond to any comments or
      observations of potential non-compliance arising from these audits with
      proposed corrective actions that are acceptable to both Parties and to
      implement these actions in a reasonable time. BMX shall reasonably
      compensate GP for employee time and any expenses incurred in connection
      with such audits, as well as for the cost of any action requested by BMX
      as a result of such audits. All information obtained in the course of any
      such audit by BMX shall be considered Confidential Information hereunder,
      but may be disclosed by BMX to regulatory agencies when and as necessary.

                                      -39-
<PAGE>
            (d) In connection with GP's manufacture of KBCs and Sample
      Collection Kits, GP will provide reasonable assistance, information and
      documentation to BMX in the investigation of complaints, MDR reportable
      events, recalls and other quality issues and will be reasonably available
      in responding to questions posed by the FDA or other authorities (the
      topics of such questions may include submissions, recalls and inquiries
      following inspections).

            (e) GP will manufacture, store, package and ship KBCs in conformance
      with applicable specifications in order to ensure the suitability, quality
      and stability of the materials. GP will maintain necessary systems and
      associated records to ascertain conformance to these specified
      requirements including environmental, monitoring and calibration systems.
      GP shall reasonably cooperate in resolving any KBC quality problems
      identified by BMX upon receipt of shipment of KBCs from GP (including
      replacement of such KBCs as the Parties agree fail to meet applicable BMX
      quality standards). Following delivery of KBCs from GP, BMX will store
      KBCs in conformance with applicable specifications in order to ensure the
      suitability, quality and stability of the materials. BMX will maintain
      adequate records to ascertain conformance to these specified requirements
      including environmental, monitoring and calibration systems.

      8.6  PRODUCT LIABILITY.

            (a) GP shall be responsible for, and shall assume the defense of and
      indemnify and hold harmless BMX and its Affiliates from and against, all
      Product Liability Claims (as defined below) arising out of or related to
      any Key Biochemistry Components supplied by GP hereunder which are
      incorporated into VIDAS Products and which are sold or distributed by BMX
      or its Affiliates hereunder. BMX shall be responsible for, and shall
      assume the defense of and indemnify and hold harmless GP and its
      Affiliates from and against, all Product Liability Claims arising out of
      or related to any and all VIDAS Products and VIDAS Instrumentation which
      are manufactured, sold and distributed by BMX hereunder, except to the
      extent that such Product Liability Claim relates to or arises out of any
      Key Biochemistry Components incorporated into such VIDAS Product or for
      which GP shall have responsibility under this Section 8.6(a), unless the
      condition or performance of such Key Biochemistry Component has been
      adversely affected by any act or omission on the part of BMX.

            (b) For purposes of this Agreement, the term "Product Liability
      Claims" shall mean any and all claims asserted against either Party or its
      Affiliates, or their respective directors, officers and agents, arising
      out of or relating to any VIDAS Products,VIDAS Instrumentation, and Key
      Biochemistry Components manufactured sold or distributed by the Parties
      hereunder, including, but not limited to, claims based on strict liability
      in tort, negligence or breach of express or implied warranty and claims
      for exemplary and consequential damages, in cases in which it is alleged
      that personal injury, death or property damage was caused by a defect in
      design, material or manufacture.

                                      -40-
<PAGE>
            (c) If either Party receives information indicating that a Product
      Liability Claim exists or has been asserted, such Party shall immediately
      notify the other Party in writing of such claim; provided, however, that
      no such notice need be given if, in the reasonable opinion of counsel to
      such Party, the giving of such notice would result in the loss of the
      ability of such Party to claim any applicable legal privileges.

            (d) The Parties shall reasonably cooperate with each other, and
      shall cause their Affiliates to reasonably cooperate with each other, in
      the investigation and defense of any Product Liability Claim. Subject to
      any applicable legal privileges, each Party shall provide, when reasonably
      requested by the Party which is obligated to defend a Product Liability
      Claim hereunder, to provide records, information and employees of such
      Party to assist the indemnifying Party or its Affiliates in the
      investigation and defense of such claim or suit; provided, however, that
      such indemnifying Party and its Affiliates shall reimburse the other Party
      for the reasonable out-of-pocket costs incurred in providing such
      assistance.

    8.7  INDEMNIFICATION FOR PRODUCT WARRANTIES. BMX shall assume the defense
of, and shall indemnify and hold harmless GP and its Affiliates from and
against, any and all claims that may be asserted against GP or its Affiliates in
connection with any express product warranties concerning the VIDAS Products and
VIDAS Instrumentation which are extended by BMX or its Affiliates in favor of
Third Parties. GP shall assume the defense of, and shall indemnify and hold
harmless BMX and its Affiliates from and against, any and all claims that may be
asserted against BMX or its Affiliates in connection with any express product
warranties concerning the KBCs which are extended by GP or its Affiliates in
favor of Third Parties.

    8.8  PATENT INFRINGEMENT CLAIMS. If either Party receives a claim by a Third
Party that any KBC or component thereof infringes a patent or misappropriates
any other right of the third Party, then such Party shall notify the other Party
promptly in writing within fifteen (15) days of receipt of such claim and the
Parties shall provide each other with all reasonable information available to
them for the defense of such claim. GP shall promptly suspend manufacture of any
KBC for BMX after receipt of notice of an infringement claim, unless BMX (i)
expressly instructs GP to continue to manufacture such KBC and (ii) agrees to
indemnify, protect, and hold harmless GP as to the subject matter of the
infringement claim with respect to the continuing manufacture of such KBC.

                                      -41-
<PAGE>
9. MARKETING

          9.1  BMX shall have the sole responsibility for marketing and sales of
VIDAS Products and VIDAS Instrumentation throughout the world (including but not
limited to the selection of accounts, advertising, promotion, and distribution
of the VIDAS Products). BMX shall use Commercially Reasonable Efforts to market
and sell the VIDAS Products and VIDAS Instrumentation. Notwithstanding the
foregoing provisions, in light of the joint development pursuant to the VIDAS
Agreement of the VIDAS Initial Products, the Parties shall jointly discuss, in
good faith, the initial marketing plans for such Products in the United States
not later than six months prior to the First Commercial Sale of any such Product
in the United States.

          9.2  Subject to applicable regulatory requirements, the packaging and
labeling for each Initial VIDAS Product shall be approved by both GP and BMX and
shall reflect the fact of each Party's contribution to such Initial VIDAS
Product. Subject to applicable regulatory requirements, the packaging and
labeling for all VIDAS Products, other than the Initial VIDAS Products and the
Sample Collection Kits, shall not bear GP's name other than in patent markings,
unless BMX has obtained GP's prior written approval to use the same; provided,
however, that to the extent reasonably requested by either Party, such packaging
and labeling shall include appropriate references to any Patents (or pending
Patent applications) to which such products are subject.

          9.3  BMX shall have sole discretion in establishing prices to
individual customers based upon prevailing market conditions, competitive
factors and other commercial considerations it reasonably deems relevant.
Royalties payable on VIDAS Products shall not be reduced through sale of VIDAS
Products in such a manner as to serve as a "loss leader" nor through marketing
of VIDAS Products, instrumentation, or other products and services in such a
manner as to distort the relative value of the VIDAS Products in relation to the
cost or value of the instrument or other products and services, when considered
in light of the primary marketing practices within the clinical diagnostic
industry (or other relevant industry, if applicable).

                                      -42-
<PAGE>
10. RELEASES

   10.1  In consideration of the promises and agreements set forth herein, the
sufficiency and receipt of all such consideration being hereby acknowledged,
upon execution of this Agreement, GP and all of its respective directors,
officers, affiliates, subsidiaries, parent companies, controlling entities,
stockholders, partners, joint ventures, employees, successors, attorneys,
agents, assigns, legal representatives, and other representatives, hereby
release, relieve, and forever discharge BMX, and its directors, officers,
affiliates, subsidiaries, parent companies, controlling entities, stockholders,
partners, joint ventures, employees, successors, attorneys, agents, assigns,
legal representatives, other representatives, and others acting in association
with them (collectively the "BMX Releasees"), in each case whether past,
present, or future, from any and all manner of claims, demands, obligations,
injunctions, actions, causes of action, suits, rights, damages, expenses,
requests for statutory or common law sanctions, or potential requests for
compensation or payment of any nature whatsoever, in law or in equity, by reason
of any matter, act or action, omission, cause, happening or thing whatsoever
that occurred, arose, or began prior to and including the date of this
Agreement, against any of the BMX Releasees, to the extent that any facts
supporting any such claims are known to the GP Releasors as of the date of this
Agreement, including, without limitation, any claims arising out of or related
to the filing or prosecution of any known patent application by BMX on or after
May 2, 1997. This release shall include all known claims under the VIDAS
Agreement, except that nothing contained in this paragraph shall (a) terminate
any ownership claim, interest, or right of GP in any property, (including
patents, inventions, and proprietary information) and/or (b) terminate any claim
by GP to enforce an express contractual obligation of BMX solely for the payment
for money pursuant to the VIDAS Agreement.

10.2  In consideration of the promises and agreements set forth herein, the
sufficiency and receipt of all such consideration being hereby acknowledged,
upon execution of this Agreement, BMX and its respective directors, officers,
affiliates, subsidiaries, parent companies, controlling entities, stockholders,
partners, joint ventures, employees, successors, attorneys, agents, assigns,
legal representatives, and other representatives (collectively the "BMX
Releasors") hereby release, relieve, and forever discharge GP and each of its
respective directors, officers, affiliates, subsidiaries, parent companies,
controlling entities, stockholders, partners, joint ventures, employees,
successors, attorneys, agents, assigns, legal representatives, and other
representatives, in each case whether past, present, or future, from any and all
manner of claims, demands, obligations, injunctions, actions, causes of action,
suits, rights, damages, expenses, requests for statutory or common law
sanctions, or potential requests for compensation or payment of any nature
whatsoever, in law or in equity, by reason of any matter, act or action,
omission, cause, happening or thing whatsoever that occurred, arose, or began
prior to and including the date of this Agreement, against any of the GP
Releasees, and to the extent that any facts supporting any such claims are known
to the BMX Releasors as of the date of this Agreement, including, without
limitation, any claim arising out of the (i) GP's having obtained license rights
for BMX under the Collins [***] patents for BMX in connection with the [***} and
(ii) GP's execution of an agreement with Chiron Corp. with respect to blood
screening and clinical

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                      -43-
<PAGE>
diagnostic products. This release shall include all known claims under the VIDAS
Agreement, except that nothing contained in this paragraph shall (a) terminate
any ownership claim, interest, or right of BMX in any property, (including
patents, inventions, and proprietary information) and/or (b) terminate any claim
by BMX to enforce an express contractual obligation of GP solely for the payment
for money pursuant to the VIDAS Agreement.

                                      -44-
<PAGE>
11. REPRESENTATIONS AND WARRANTIES

      11.1  REPRESENTATIONS AND WARRANTIES OF GP. GP represents to BMX that:

            (a) POWER AND AUTHORITY. The execution and delivery of this
      Agreement and the performance of the transactions contemplated hereby have
      been duly authorized by all appropriate corporate action, and GP has all
      requisite power and authority to enter into this Agreement and to perform
      its obligations hereunder, and this Agreement constitutes a valid and
      binding obligation of GP, enforceable against GP in accordance with its
      terms.

            (b) NO BREACH. The performance by GP of any of the terms and
      conditions of this Agreement on its part to be performed does not and will
      not constitute a breach of any other agreement or understanding, whether
      written or oral, to which it or any of its Affiliates is a Party.

            (c) RIGHTS TO INTELLECTUAL PROPERTY. To the best of GP's knowledge,
      GP has good and valid title to or rights in, and has the right to license
      hereunder pursuant to license, sublicense, agreement or permission, the GP
      Technology. GP is not aware of any claims for royalties, and has not
      contracted for payment of any royalties, with respect to the GP Technology
      other than have previously been disclosed in writing to BMX.

            (d) CONSENTS AND APPROVALS. No consent, approval, authorization,
      license, order or permit of, or declaration, filing or registration with,
      any governmental entity, or any other person or entity, is required to be
      made or obtained by GP or any Affiliate of GP in connection with the
      execution and delivery of this Agreement and the consummation of the
      transactions contemplated hereby.

      11.2  REPRESENTATIONS AND WARRANTIES OF BMX. BMX represents to GP that:

            (a) POWER AND AUTHORITY. The execution and delivery of this
      Agreement and the performance of the transactions contemplated hereby have
      been duly authorized by all appropriate corporate action, and BMX has all
      requisite power and authority to enter into this Agreement and to perform
      its obligations hereunder, and this Agreement constitutes a valid and
      binding obligation of BMX, enforceable against BMX in accordance with its
      terms.

            (b) NO BREACH. The performance by BMX of any of the terms and
      conditions of this Agreement on its part to be performed does not and will
      not constitute a breach of any other agreement or understanding, whether
      written or oral, to which it or any of its Affiliates is a Party.

            (c) RIGHTS TO INTELLECTUAL PROPERTY. To the best of BMX's knowledge,
      BMX has good and valid title to or rights in, and has the right to license
      hereunder pursuant to license, sublicense, agreement or permission, the
      BMX Technology.

                                      -45-
<PAGE>
            (d) CONSENTS AND APPROVALS. No consent, approval, authorization,
      license, order or permit of, or declaration, filing or registration with,
      any governmental entity, or any other person or entity, is required to be
      made or obtained by BMX or any Affiliate of BMX in connection with the
      execution and delivery of this Agreement and the consummation of the
      transactions contemplated hereby.

   11.3  INDEMNIFICATION. Each Party shall indemnify and hold harmless the other
Party and each of its Affiliates, their respective directors, officers,
employees and agents from and against any and all losses, liabilities, damages,
judgments, awards or costs (including, without limitation, reasonable attorneys'
fees and expenses) arising out of or resulting from (i) any breach or other
default by the indemnifying Party of any of the representations, warranties or
undertakings made by such Party in this Article 11, and (ii) any failure by such
indemnifying Party or its Affiliates to perform or discharge any of the
covenants or agreements contained in this Agreement.

   11.4  WARRANTY DISCLAIMER; LIMITATIONS. NOTWITHSTANDING ANY OTHER PROVISION
HEREIN TO THE CONTRARY, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF
ANY KIND, EXPRESSED OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY AS
TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH RESPECT TO THE
LICENSES GRANTED HEREUNDER OR ANY OF THE PRODUCTS OR TRANSACTIONS CONTEMPLATED
HEREBY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY LOST PROFITS OR
OTHER SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES RESULTING FROM THE GRANT OR
EXERCISE OF LICENSES HEREUNDER OR THE TRANSACTIONS CONTEMPLATED HEREBY. NEITHER
BMX NOR GP MAKES ANY REPRESENTATION THAT THE LICENSED PRODUCTS WILL NOT INFRINGE
ANY PATENT OR OTHER PROPRIETARY RIGHT WHICH IS NOT THE SUBJECT OF THE LICENSE
RIGHTS GRANTED HEREUNDER OR OTHERWISE OBTAINED.

                                      -46-
<PAGE>
12. CONFIDENTIALITY; PUBLICATION

      12.1  CONFIDENTIALITY. Each Party hereto shall maintain the Confidential
Information of the other Party in confidence, and shall not disclose, divulge or
otherwise communicate such Confidential Information to any Third Party, or use
it for any purpose, except that such Party shall have the right to disclose
Confidential Information to its Affiliates and to its employees who have a need
to know such information in order to fulfill the objectives of this Agreement.
Each Party hereby agrees to exercise its best efforts precautions to prevent and
restrain the unauthorized disclosure of such Confidential Information by any of
its directors, officers, employees, consultants, subcontractors, agents,
collaborators, and Affiliates, which shall include obtaining appropriate secrecy
or confidentiality undertakings from such persons. Each Party shall be
responsible for any breach of any such undertakings by its employees, agents or
representatives. Each Party shall also take all steps necessary to insure that
no employees or other agents of such Party who are not directly involved in the
activities contemplated by this Agreement do not have access to any Confidential
Information of the other Party. Without limiting the foregoing, each Party
agrees to use its best efforts to maintain in confidence the Know-How and other
trade secrets licensed to the other Party.

      12.2 AUTHORIZED DISCLOSURE. The provisions of Section 12.1 shall not apply
to any Confidential Information disclosed hereunder which:

            (a) was known or used by the receiving Party or its Affiliates prior
      to its date of disclosure to the receiving Party, as evidenced by the
      prior written records of the receiving Party or its Affiliates; or

            (b) either before or after the date of the disclosure to the
      receiving Party is lawfully disclosed without restriction on disclosure to
      the receiving Party or its Affiliates by an independent, unaffiliated
      Third Party rightfully in possession of the Confidential Information; or

            (c) either before or after the date of the disclosure to the
      receiving Party becomes published or generally known to the public through
      no fault or omission on the part of the receiving Party or its Affiliates;
      or

            (d) is required to be disclosed by the receiving Party to comply
      with applicable laws or to comply with governmental regulations or the
      order of a court of law, provided that the receiving Party provides prior
      written notice of such disclosure to the other Party and takes reasonable
      and lawful actions to avoid and/or minimize the degree of such disclosure,
      which shall include, without limitation, seeking appropriate protective
      orders, providing such information under seal or in camera or similar
      protective devices.

                                      -47-
<PAGE>
   12.3  PUBLICATIONS. The following restrictions shall apply with respect to
the disclosure in scientific journals or publications by any Party or any of its
Affiliates or any employee or consultant of any Party or any of its Affiliates
of Confidential Information of the other Party:

            (a) Each Party shall retain all publishing/presentation rights for
      its Confidential Information (regardless of medium, including, without
      limitation, paper, graphic, electronic, optical and multimedia).

            (b) The Parties will jointly have publication/presentation rights
      for all Confidential Information that is jointly-owned hereunder;
      provided, however, that proper and reasonable attributions to the other
      Party are made, if applicable, and subject to the prior approval
      requirements of Section 12.3(c).

            (c) Each Party will furnish to the other accurate and complete
      copies of any proposed publication or transcript of any proposed
      presentation at least thirty (30) days prior to the date of proposed
      presentation or submission of a manuscript for publication, in each case
      either because there is patentable subject matter which requires
      protection and/or there is Confidential Information of a Party contained
      in the proposed publication or presentation. Any Confidential Information
      or patentable subject matter of a Party identified by such Party will be
      deleted from the proposed publication or presentation unless such Party
      consents to its inclusion. Neither Party shall enter into any agreements
      or other commitments, with any employees, agents or other Third Parties
      which conflict with or otherwise interfere with the provisions of this
      Section.

                                      -48-
<PAGE>
13. TERMINATION

      13.1 TERMINATION BY MUTUAL AGREEMENT. The Parties may at any time
terminate this Agreement by written agreement executed by both BMX and GP.

      13.2 TERMINATION BY BMX. At any time after December 30, 2004, this
Agreement (and all licenses and rights granted herein) may be terminated by BMX
upon written notice of termination to GP. Thereafter, all licenses and rights
granted by this Agreement shall terminate automatically on the effective date of
the notice of termination. Once GP has paid $750,000 for Clinical Trial Costs
pursuant to section 6.5, the date on which BMX may first terminate this
Agreement unilaterally shall be extended to December 30, 2005.

      13.3 TERMINATION FOR MATERIAL BREACH. Each Party shall have the right, in
addition to and not in limitation of any other right and remedies it may have at
law or in equity, to terminate this Agreement after sixty (60) days prior
written notice to the other upon the occurrence of any of the following:

            (a) Upon or after the bankruptcy, insolvency, dissolution or winding
      up of the other Party (other than a dissolution or winding up for the
      purpose of reconstruction or amalgamation); or

            (b) Upon or after the breach of any material provision of this
      Agreement by the other Party if the breaching Party has not cured such
      breach within the sixty (60) day period following written notice of
      termination by the non-breaching Party.

If BMX is the non-breaching Party, all licenses granted to BMX under Section
3.1(a) of this Agreement which are in effect at the time of termination shall
survive such termination for so long as BMX is not in breach of its obligations
to GP under this Agreement, which survive such termination so long as such
licenses remain in effect. Without limiting the foregoing, if the Agreement is
terminated due to BMX being the breaching Party, BMX shall immediately cease and
desist from manufacturing, developing, upgrading, selling, and distributing
VIDAS Products (but without prejudice to BMX's right to conduct independent
research and development activities with the BMX Technology).

      Notwithstanding any other provision of this Agreement, a Party receiving a
written notice of termination pursuant to subparagraph (b) above shall have the
right to dispute the the existence of a default or material breach or the
adequacy or remedy thereof, the alleged breaching Party may require that the
right to terminate this Agreement be determined by arbitration pursuant to
Section 15.2 and in the event the arbitrator(s) determine that there were
reasonable grounds for the alleged breaching party so charged to dispute
termination and that the alleged breaching party acted in good faith, the
arbitrator(s) may afford reasonable opportunity to cure upon such terms as they
may direct. The Termination Date in the event of termination for breach shall be
the date duly fixed in any valid notice of termination by the non-breaching
Party (consistent with the aforesaid cure periods), except that in the case of
any arbitration as to such breach, the arbitrators may determine the Termination
Date.

                                      -49-

<PAGE>
   13.4 SURVIVING OBLIGATIONS. Promptly after termination of this Agreement,
each Party shall return or dispose of any Know-How and Confidential Information
of the other in the accordance with the instructions of the other, including
without limitation any compounds, assays or other biological or chemical
materials; provided that this requirement shall not apply to a Party so long as
it retains a license pursuant hereto. Notwithstanding any other provision of
this Agreement, Articles 1, 2, 7 (except -- if termination results from any
breach by GP-- section 7.10), 10, 11, 12, and 15 hereof shall survive the
expiration or termination of this Agreement. Section 5.3 shall also survive
termination. Termination shall not affect any obligation of BMX under Article 4
of this Agreement which accrued prior to the date of termination.

                                      -50-
<PAGE>
14. EXPORT

      14.1 ACKNOWLEDGMENT. The Parties acknowledge that the export of technical
data, materials or products is subject to the exporting Party receiving all
necessary export licenses and that the Parties cannot be responsible for any
delays attributable to export controls which are beyond the reasonable control
of either Party. Each Party covenants and agrees to comply with all applicable
treaties, laws, statutes, rules and regulations of any federal, state, local or
foreign governmental entity or instrumentality, including, without limitation,
the provisions of the United States Export Administration Act of 1969, as
amended, and all other applicable export laws, restrictions and regulations of
the Department of Commerce and the FDA. The receiving Party shall provide the
exporting Party with any information, materials, certifications or other
documents which may be reasonably required in connection with such export laws,
restrictions and regulations.

      14.2 WRITTEN ASSURANCES. Without limitation of the foregoing, and in
support of maintaining a general license for the export of technical data under
this Agreement, a Party receiving an export agrees to not knowingly export or
reexport any technical data or materials furnished to such Party under this
Agreement, any part thereof or any direct product thereof, directly or
indirectly, without first obtaining permission to do so (if required) from the
United States Department of Commerce, the FDA and/or other appropriate United
States governmental agencies, into any country to which restrictions apply.

                                      -51-
<PAGE>
15. GOVERNING LAW; DISPUTE RESOLUTION

      15.1 GOVERNING LAW. This Agreement shall be governed by and interpreted in
accordance with the laws of New York (without regard to its or any other
jurisdiction's choice of law principles), except that any arbitration hereunder
shall be subject to the federal law applicable to arbitration.

      15.2 ARBITRATION. In the event of any controversy or claim relating to,
arising out of or in any way connected to any provision of this Agreement or any
of the Interrelated Agreements ("Dispute"), the Parties shall seek to settle
their differences amicably between themselves, including entering into
non-binding mediation. Any unresolved Dispute shall be finally resolved by final
and binding arbitration in accordance with this Section 15.2. Whenever a Party
shall decide to institute arbitration proceedings, it shall give written notice
to that effect to the other Party. The Party giving such notice shall refrain
from instituting the arbitration proceedings for a period of ten (10) days
following such notice to allow the Parties to attempt to resolve the Dispute
between themselves. If the Parties are still unable to resolve the dispute, the
Party giving notice may institute the arbitration proceeding under the rules of
Conciliation and Arbitration of the International Chamber of Commerce as then in
effect ("ICC Rules"). Arbitration shall be held in New York, New York. The
arbitration shall be conducted before three arbitrators, with each Party to
select one arbitrator and with the third arbitrator to be appointed in
accordance with ICC Rules. The arbitrators shall undertake in writing as a
condition of service to conduct proceedings in a speedy and efficient manner to
render the award promptly after the final arbitration hearing, and further shall
confirm in writing to the President of the Court of Arbitration of the
International Chamber of Commerce that such undertaking is being or has been
fulfilled, or shall report the reasons for any failure of fulfillment, as a
condition for any application for fees. If so requested by either Party,
preparation of any Terms of Reference referred to in ICC Rules shall be waived
and the matters at issue in the Dispute shall be determined by the arbitrators
based on the timely submissions of the Parties, the arbitrators shall not have
the power to award punitive damages or any award of multiple damages under this
Agreement and such awards are expressly prohibited. Any arbitral award shall be
by majority vote and shall be final and binding on the Parties. Judgment on the
award may be entered in any court having jurisdiction. Except to the extent
entry of judgment and any subsequent enforcement may require disclosure, all
matters relating to the arbitration, including the award, shall be held in
confidence by the Parties. Nothing contained in this Section 15.2 shall prevent
either Party from seeking temporary restraining orders, injunctions or such
other relief in any court of competent jurisdiction.

                                      -52-
<PAGE>
16. GENERAL PROVISIONS

      16.1 PUBLICITY. Neither Party, nor any of its Affiliates, shall originate
any publicity, news release or other public announcement, written or oral,
relating to this Agreement or the existence of an arrangement between the
Parties, without the prior written approval of the other Party, which approval
shall not be unreasonably withheld, except as otherwise required by law.

      16.2 NOTICES. All notices required or permitted to be given under this
Agreement shall be in writing and shall be (a) mailed by registered or certified
mail, FedEx, or DHL, addressed to the signatory to whom such notice is required
or permitted to be given and (b) transmitted by facsimile to the number
indicated below. All notices shall be deemed to have been given when delivered
by the United States Postal Service, FedEx, or DHL to the addressee at the
address listed below.

      All notices to BMX shall be addressed as follows:

                           bioMerieux, Inc.
                           595 Anglum Road
                           Hazelwood, Missouri 63042-2395
                           Attention: President

                           Facsimile: (314) 731-7412

      All notices to GP shall be addressed as follows:

                           Gen-Probe Incorporated
                           10210 Genetic Center Drive
                           San Diego, California 92121-1589
                           Attention: President

                           Facsimile: (858) 410-8637

      Any Party may, by written notice to the other, designate a new address or
fax number to which notices to the Party giving the notice shall thereafter be
mailed or faxed.

      16.3 FORCE MAJEURE. In the event that either Party is prevented from
performing or is unable to perform any of its obligations under this Agreement
(other than the obligation to pay money) due to any act of God; fire; casualty;
flood; war; strike; lockout; failure of public utilities; injunction or any act,
exercise, assertion or requirement of governmental authority; epidemic;
destruction of production facilities; riots; insurrection; inability to procure
or use materials, labor, equipment, transportation or energy; or any other cause
beyond the reasonable control of the Party invoking this Section 16.3 if such
Party shall have used its best efforts to avoid such occurrence ("Force
Majeure"), such Party shall give notice to the other Party in writing promptly,
and thereupon the affected Party's performance shall be excused and the time for
performance shall be extended for the period of delay or inability to perform
due to such occurrence.

                                      -53-
<PAGE>
      16.4 CALENDAR AND BUSINESS DAYS. Unless otherwise expressly stated to be
business days, all references to days shall mean calendar days; provided,
however, that if the last date or the deadline for the giving of notice or
performance of any other act or fulfillment or satisfaction of any condition set
forth in this Agreement shall fall on a day which is not a business day, then
the time for the giving of such notice or performance of such act or fulfillment
or satisfaction of such condition shall be extended to the next business day. As
used herein, the term "business days" shall mean all days other than Saturdays,
Sundays or state or federal holidays.

      16.5 ENTIRETY OF AGREEMENT; EFFECT ON VIDAS AGREEMENT. This Agreement and
the Exhibits and Schedules hereto (which Exhibits and Schedules are deemed to be
a part of this Agreement for all purposes) contain the full understanding of the
Parties with respect to the subject matter hereof and prospectively supersede
all prior understandings and writings relating thereto (including, without
limitation, the VIDAS Agreement, except as interpretation of the same may be
necessitated hereby or otherwise required for determination of the rights of the
Parties prior to or as of the Effective Date hereof) and shall be deemed a
single, integrated agreement. Nothing contained in this section shall affect the
rights of the Parties with respect to the ownership of any invention pursuant to
the terms of the VIDAS Agreement. Nothing contained in this section shall affect
other agreements between the parties which are not directly related to the
subject matter of this agreement (including, without limitation, the ANAIS
Agreement). No waiver, alteration, consent or modification of any of the
provisions hereof shall be binding unless made in writing and signed by the
Parties by their respective officers thereunto duly authorized.

      16.6 NON-WAIVER. The waiver by either Party of a breach or a default of
any provision of this Agreement by the other Party shall not be construed as a
waiver of any succeeding breach of the same or any other provision, nor shall
any delay or omission on the part of either Party to exercise or avail itself of
any right, power or privilege that it has or may have hereunder operate as a
waiver of any right, power or privilege by such Party.

      16.7 NO PARTNERSHIP OR AGENCY. Nothing herein shall be deemed to
constitute either Party as the agent or representative of the other Party, or
both Parties as joint venturers or partners for any purpose. Each Party shall be
an independent contractor, not an employee or partner, of the other Party, and
the manner in which a Party renders its services under this Agreement shall be
within such Party's sole discretion. Neither Party shall be responsible for the
acts or omissions of the other Party, and neither Party will have authority to
speak for, represent or obligate the other Party in any way without prior
written authority from the other Party.

      16.8 SEVERABILITY. In the event that any provision of this Agreement is
held by a court of competent jurisdiction to be unenforceable because it is
invalid or in conflict with any law of any relevant jurisdiction, the validity
of the remaining provisions shall not be affected, and the rights and
obligations of the Parties shall be construed and enforced as if the Agreement
did not contain the particular provisions held to be unenforceable.

      16.9 ASSIGNMENT. Except as otherwise provided in this Agreement, neither
this Agreement nor any of the rights or obligations hereunder may be directly or
indirectly assigned by either Party without the prior written consent of the
other Party, which shall not

                                      -54-
<PAGE>
be unreasonably withheld; provided, however, that either Party may assign
without the consent of the other Party to an Affiliate; provided further,
however, that any assignment or transfer of rights or obligations arising from
or related to any assignment to an Affiliate, or by any merger, consolidation,
other Change in Control, or similar transaction shall be subject to the consent
of the other Party, not to be unreasonably withheld, if it directly or
indirectly involves the acquisition of greater than fifty percent (50%) of the
total voting power of a Party or an Affiliate by any of the following parties:
[***] Any purported assignment or transfer in violation of this section shall be
void. Any permitted assignee or transferee shall assume all obligations of its
assignor or transferor under this Agreement, provided that the assigning or
transferring Party shall remain liable on all obligations which accrued prior to
assignment or transfer.

    16.10 SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and inure
to the benefit of the Parties hereto and their permitted successors and
permitted assigns.

    16.11 HEADINGS. The headings contained in this Agreement are for convenience
of reference only and shall not be considered in construing this Agreement.

    16.12 DRAFTING PARTY. The provisions of this Agreement, and the documents
and instruments referred to in the Agreement, have been prepared, examined,
negotiated and revised by each Party to this Agreement and their respective
counsel, and no implication will be drawn and no provision will be construed
against either Party to this Agreement by virtue of the purported identity of
the drafter of this Agreement, or any portion of this Agreement.

    16.13 ENGLISH LANGUAGE. This Agreement may be translated into one or more
languages for the convenience of the Parties, provided that the English language
version shall be controlling for all purposes hereunder. All reports, data,
information, notices, schedules, plans, records and other information required
to be provided pursuant to this Agreement by any Party to this Agreement will be
in the English language.

    16.14 LIMITATION OF LIABILITY. No Party shall be liable to another for
indirect, incidental, consequential or special damages, including but not
limited to lost profits, arising from or relating to any breach of this
Agreement, regardless of any notice of the possibility of such damages. Nothing
in this Section is intended to limit or restrict the indemnification rights or
obligations of any Party.

    16.15 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be an original and all of which shall
constitute together the same document.

    16.16 NO THIRD-PARTY BENEFICIARIES. Nothing in this Agreement, express or
implied, is intended to confer on any person other than the Parties hereto, or
their respective

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
                                      -55-
<PAGE>
permitted successors and assigns, any benefits, rights or remedies.

    16.17 PUBLIC ANNOUNCEMENTS. Neither Party shall issue any press release,
statement or other announcement to the general public or to the general or trade
press relating to this Agreement or the transactions contemplated hereby, with
the agreement of the other Party, such agreement not to be unreasonably
withheld.

      IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their properly and duly authorized officers or representatives as of
the date first above written.

GEN-PROBE INCORPORATED                    BIOMERIEUX, INC.

By:  /s/ Henry L. Nordhoff             By:  /s/ Albert A. Luderer
 _________________________________      _________________________________
         Henry L. Nordhoff                    Albert A. Luderer
President and Chief Executive Officer     President

                                      -56-
<PAGE>
                                    EXHIBIT A

                           KEY BIOCHEMISTRY COMPONENTS

      All enzymes used in transcription-based amplification (including TMA and
variations and improvements to TMA) for use in VIDAS Assays.

      All biochemical components used for amplification of amplicon of target
with TMA.

      All probes, primers, and oligonucleotides used in VIDAS Assays.

      Nucleic acids used for positive and negative controls, standards,
calibrators, and for quality control of VIDAS Assay components and VIDAS kits.

      This exhibit is subect to all limitations of section 8.1(a) of the
foregoing agreement, i.e., that GP's right and obligation to manufacture KBC's
for Vidas Products are limited to (1) those KBCs to be incorporated into the
VIDAS Initial Products which GP has developed prior to December 30, 2000 and 2)
those non-product specific ("Generic") KBCs which GP has developed prior to
December 30, 2000 and which are to be incorporated into, or used for development
of, VIDAS Products.
<PAGE>
                                    EXHIBIT B

                                 OPTION TARGETS

[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.
<PAGE>
                                    EXHIBIT C

                    BMX FOREIGN CURRENCY CONVERSION PRACTICES

<PAGE>
                               Currency Exchange

     The currency exchange rates used to convert amounts stated in currencies
other than U.S. Dollars to U.S. dollars by Affiliates of BMX shall be as
follows.

     1.   Amounts initially stated in French francs shall be converted into U.S.
dollars on a monthly basis, using a separate currency rate of exchange for each
of the three months in the quarter. With respect to each such month, a "monthly
average" of the reported conversion franc to dollar conversion rate, the
conversion rate entitled the "Cours Indicatif de la Banque de France", for each
Wednesday in such month, as published in La Tribune, shall be calculated, and
applicable amounts converted using such conversion rate. The report pursuant to
Section 5.6 shall state the relevant dollar figures for the applicable quarter
in U.S. dollars as so calculated, and shall state the conversion rates
applicable for each month in such quarter.

     2.   Amounts initially stated neither in French francs nor in U.S. dollars
shall be converted to French francs on a monthly basis, using a separate
currency rate of exchange for each of the three months in the quarter, and such
amounts, as stated in French francs, shall then be converted to U.S. dollars in
the manner set forth in paragraph 1. The report pursuant to Section 5.6 shall
state the aggregate relevant dollar figures for the applicable quarter in U.S.
dollars as so calculated, and shall state the conversion rates applied in each
month to calculate the conversion to French francs and the conversion to U.S.
dollars. The conversion rate applied to calculate the conversion of such
currencies to French francs shall be the "monthly average" of the reported
applicable currency to French franc conversion rate, for each Wednesday in such
month, as published in La Tribune, which rate shall be the "Cours Indicatif de
la Banque de France", if available, or otherwise the "Cours du Fixage de la
B.F.C.E." or another applicable rate.
<PAGE>
                                    EXHIBIT D

                        DEVELOPMENT TRANSITION WORK PLAN
<PAGE>
                  VIDAS PROBE DEVELOPMENT TRANSITION WORK PLAN
                                  GEN-PROBE/BMX
                                  CONFIDENTIAL

This work plan describes the obligations of GP and BMX with respect to the
Development Transition which the Parties believe are necessary to accomplish the
Development Transition as described in the accompanying Vidas License,
Development and Cooperation Agreement. It is not the intention of this work plan
to address or provide for the transfer of manufacturing capability from GP to
BMX or to address issues concerning supply of key biochemistry components
("KBC's"). Each of these subjects is addressed by the accompanying Vidas
License, Development and Cooperation Agreement and may be further addressed by
the parties in supplemental work plans or supplemental agreements as provided in
such Agreement.

This work plan is subject to and controlled by the terms of the Vidas License,
Development and Cooperation Agreement.

The specific VIDAS PROBE assays addressed in this work plan are CT, MTB, GC,
CT/GC Combo (screen / discreet), and qHIV.

GP EMPLOYEE SUPPORT

In order to support the development transition activities required of it, GP
shall make available such personnel as shall be reasonably necessary to allow
the Development Transfer as described in the Vidas Agreement. GP and BMX
currently estimate and GP will dedicate the following full-time equivalent
support, listed by product and reagent:

<TABLE>
<CAPTION>
Gen-Probe Staffing (at end of quarter)
ITEM         PROJECT/ACTIVITY        3Q00     4Q00
----         ----------------        ----     ----
<S>          <C>                     <C>      <C>
     1       MTB                      2.5      2.5
     2       CT                       0.5       0
     3       GC                       0.5      0.5
     4       QHIV AND CT/GC SCREEN    0.5      0.5
                                      ---      ---
             TOTAL                    4.0      3.5
</TABLE>
<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

Included within the personnel referred to above, GP shall make the following GP
employees reasonably available for consultation with BMX on development
transition matters: R. Johnson, J. Burns, and M. Longiaru.

In the event either Party during the Transition Period believes that the
activities identified in this Work Plan will not be completed before December
30, 2000, such Party shall immediately inform the other Party. Upon such notice,
the Parties shall promptly attempt to identify the cause of the delay and shall
dedicate such resources as shall be reasonably necessary to rectify the problem,
subject always to GP's right to limit the number of GP personnel assigned to the
development transition in accordance with the staffing levels set forth above.

As set forth in the Vidas Agreement, the Development Transition period and
related GP Dedicated Transition activities will terminate as of December 30,
2000 unless GP has failed, solely due to its own fault, to accomplish any action
required by Development Transition work plan at which time the Development
Transition period will be extended until such action has be accomplished by
Gen-Probe.

GENERAL DESCRIPTION OF BMX DEVELOPMENT TRANSITION ACTIVITIES

Prior to the date of the accompanying Vidas License, Development And Cooperation
Agreement, BMX has assumed lead responsibility for development of all Vidas
Probe Assays. BMX shall be primarily responsible for all development activities
after the effective date of the Vidas License, Development and Cooperation
Agreement.

BMX SUPPORT

In order to support the development transition activities required of it, BMX
shall make available such personnel and facilities as may be reasonably required
to accomplish BMX's Development Transition activities. Among other things, BMX
shall provide adequate support for clinical site training and technical support.

                                       2
<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

BMX OBLIGATION RE COMPLETION OF VERIFICATION LOTS

BMX will deliver products for verification according to the schedule set forth
below.

               CT Verification lots to be complete by [***]
               No T lots are planned to be built.
               CT Verification Design Review - [***]
               CT P1 build to start [***]
               MTB lot V4 available for Verification testing [***]
               MTB lot V5 available for Verification testing [***]
               MTB P1 build to start [***] with a Verification Design Review
               in [***].

The parties agree that this schedule and the above allocation of GP resources
allows for GP to complete GP's Verification activities for the MTB assay by
December 30, 2000. This work plan also allows GP staff to be available for
consultation in design and initiation of Verification activities testing for the
CT assay, and completion of Development activities for GC.

In the event that BMX fails to deliver Vidas MTB Probe testing materials to GP
or to build CT products according to the schedule set forth above, but delivers
such materials or products within 30 days of the scheduled date, GP's time to
perform the activities required of GP hereunder shall be extended for 30 days.
In the event that BMX fails to deliver Vidas MTB Probe testing materials to GP
or to build CT products within 30 days of the schedule set forth above, then
GP's only obligation with respect to such materials and products shall be to use
commercially reasonable efforts to accomplish the activities assigned to GP
hereunder. In the event that BMX fails to deliver Vidas MTB Probe testing
materials to GP or to build CT products according to the schedule set forth
above, so that one of the two preceding sentences applies as of December 30,
2000, then the Milestone Payment due pursuant to Section 6.11 of the Vidas
License, Development and Cooperation Agreement shall be immediately due.

GP ACTIVITIES CONCERNING ASSAY-SPECIFIC INFORMATION

As part of the Development Transition, GP shall transfer from GP to BMX
knowledge, records, procedures, work instructions, formulations, and Know-How,
necessary for the development of the VIDAS Products or in carrying out the tasks
as previously performed by GP under the Vidas Agreement. GP will undertake the
following specific activities with the intent to complete all work by December
30, 2000.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3
<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

1. MTB

-       GP will undertake support of BMX's Verification phase activities for the
        Vidas Probe MTB product, in accordance with the GP staffing levels set
        forth above. [***]

        [***]

2. CT

[***]

3. GC

[***]

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       4
<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

4. CT/GC COMBO

      [***]

5. QHIV

      [***]

FURTHER COOPERATION

Technical and Regulatory Support. After the Development Transition Period, GP
shall provide technical and regulatory support with respect to protocol review
and suggestions for trouble-shooting on the Vidas Probe MTB, CT, NG, CT/GC
Combo, and QHIV assays in accordance with Section 6 of the accompanying Vidas
License, Development And Cooperation Agreement.

GP Activities Concerning Assay-Specific Information Required For Writing
Submissions To Regulatory Agencies. GP shall prepare and deliver to BMX upon
BMX's request for each respective Vidas Probe Assay, those portions of
submissions to regulatory authorities concerning Key Biochemistry Components
("KBC's"). Gen-Probe will be responsible for defending KBC formulations during
any audit by FDA or other regulatory authority. In particular, GP will prepare
submission sections that address the following:

                                       5

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

1. MTB

      [***]

2. CT

      [***]

3. GC

      [***]

4. QHIV

      [***]

                                       6

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
VIDAS PROBE WORKPLAN 2000
GEN-PROBE/BMX
Confidential

None of the activities described in this "Further Cooperation" section shall be
considered Development Transition Period activities and conclusion of
Development Transition shall not be postponed by reason of GP's potential
obligations under this section.

                                       7
<PAGE>
                                    EXHIBIT E

                         STANDARD GP PURCHASE ORDER FORM

<PAGE>
[GEN-PROBE LOGO]
 10210 GENETIC CENTER DRIVE
 San Diego, CA 92121-4362    REQUISITION DATE     DATE REQUIRED  P.O. NUMBER

                              PURCHASE REQUISITION
[]SERVICE []EXPENSE []CONSULTANT []STANDING ORDER []CHECK REQUEST []CHANGE ORDER
________________________________________________________________________________
REQUESTOR           MAIL STATION        EXTENSION      APPROVAL SIGNATURE
                                                       (Please Write Legibly)
________________________________________________________________________________
DELIVER TO          MAIL STATION        EXTENSION      APPROVAL SIGNATURE
                                                       (Please Write Legibly)
________________________________________________________________________________

SHIP TO:  []GENETIC CENTER    []OTHER:       ACCOUNT
                                             NUMBER   []-[][]-[][]-[][][][][]
________________________________________________________________________________

     RECOMMENDED SOURCE                    SUPPLIER
________________________________________________________________________________
NAME                                    NAME

________________________________________________________________________________
ADDRESS                                 ADDRESS

________________________________________________________________________________
CITY, STATE, ZIP                        CITY, STATE, ZIP

________________________________________________________________________________
PHONE               FAX                 PHONE               FAX

________________________________________________________________________________
CONTACT             VENDOR CODE         CUSTOMER ACCT.#     VENDOR CODE

________________________________________________________________________________
SHIP VIA                                ORDER DATE     CONFIRM TO     SALES
                    ESTIMATED                                         ORDER NO.
                    FREIGHT CHARGE
________________________________________________________________________________
F                                       P.O. TYPE      BUYER          TERMS
O [] FACTORY _________________________
B [] DESTINATION [] PREPAID [] COLLECT
________________________________________________________________________________

ITEM QTY  UOM    PART NUMBER       DESCRIPTION    EST.  QUOTED    EXT.     DEL.
                                                 PRICE   PRICE   PRICE     DATE
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
________________________________________________________________________________
SPECIAL INSTRUCTIONS                                       TOTAL COST

        [] THIS REQUISITION MAY AFFECT THE QUALITY OF GEN-PROBE PRODUCTS
             WHITE-PURCHASING    YELLOW-REQUESTOR    PINK-INTERNAL
<PAGE>
               THIS PURCHASE ORDER IS SUBJECT TO AND INCLUDES THE
                         FOLLOWING TERMS AND CONDITIONS

1. AGREEMENT:  This Purchase Order becomes the exclusive agreement between the
parties for the goods, subject to the terms and conditions hereof, when accepted
by acknowledgment or commencement of performance by Vendor. Additional or
different terms proposed by Vendor shall not apply, and no change in,
modification of or revision to this Purchase Order shall be valid unless
accepted in writing by Buyer. Acceptance of goods delivered under this Purchase
Order shall be made subject to the terms herein, and mere acceptance of
delivered goods shall in no way be considered to be an acceptance of any
additional, different, changed, modified or revised terms. Buyer must be
notified in accordance with Section 27 of any change in delivery date. If this
Purchase Order is for services, the term "goods" as used herein shall mean
"services".
2. CHANGES/CANCELLATION: This order or any contract made pursuant hereto may be
changed or cancelled by the Buyer at his option by written notice at any time.
Any result in contract price differential shall be equitably adjusted in
writing. In the event of cancellation, reimbursement for labor and materials
already used on this order will be made and the materials so paid for will be
shipped to Buyer.
3. PAYMENT:    All taxes imposed upon the sale of the goods, whether by
federal, state or municipal government, shall be paid by Vendor unless
otherwise indicated on this Purchase Order. Any adjustment to Vendor's invoices
due to shortages, late deliveries, rejection or other failure to comply with
the requirements of this Purchase Order may, at Buyer's option, be made by
Buyer before payment. Failure to so adjust shall not deprive buyer of the right
to do so thereafter. Payment of invoices may be withheld pending final
acceptance. Payment, with or without delivery, for all or part of the goods
covered hereby does not constitute acceptance. Except as otherwise noted in
this Purchase Order, Buyer shall not have any liability for payment of extras
or Vendor's expenses unless such expenses or extras have been authorized in
writing in advance by Buyer.
4. INDEPENDENT CONTRACTOR:    Services provided hereunder shall be performed by
Vendor solely as an independent contractor. All personnel furnished by Vendor
to provide services to Buyer shall at all times be the employees of Vendor and
shall not be deemed to be the employees or agents of Buyer.
5. MATERIALS FURNISHED BY BUYER:   If Buyer furnishes any material for
fabrication of the goods, Vendor (1) shall not substitute any other material in
such fabrication without Buyer's written consent, and (2) agrees that title to
such material shall not be affected by incorporation in or attachment to any
other property. Vendor shall use any designs, tools, patterns, drawings,
information and equipment furnished by Buyer only in the performance of this
Purchase Order. Upon completion or termination of this Purchase Order, all items
furnished by Buyer shall be returned to Buyer or disposed of pursuant to
instructions issued by Buyer. Vendor shall be liable for any loss or damage to
property furnished by Buyer while such property is in Vendor's possession.
6. ASSIGNMENT:    Vendor shall not assign or delegate this Purchase Order or
any interest under it without the prior written consent of Buyer, and any
unauthorized assignment or delegation shall be void and ineffective for all
purposes.
7. TITLE ON TERMINATION: In the event of termination, Buyer may give notice
concurrent with or subsequent to the notice effecting termination that all
right of possession, title and interest in or to all or any portion of the
materials, tooling, work in process or completed goods covered by this Purchase
Order shall pass to Buyer effective upon Vendor's receipt of such notice.
8. PACKING AND SHIPPING: Vendor shall ship only as specified in this Purchase
Order or as subsequently directed in writing by Buyer. All extra charges of any
kind, including but not limited to insurance, packing, crating, excess
transportation costs, storage, etc. will be borne by Vendor.
9. CONFIDENTIALITY AND RETURN OF PROPRIETARY MATERIALS:  Vendor agrees that
Vendor will not, during the course of providing goods or services under this
Purchase Order and for a period of five (5) years thereafter, disclose directly
or indirectly to any person or entity, or copy, reproduce or use, any
information designated as confidential Information, trade secret or information
treated as confidential by Buyer ("Confidential Information") known, learned or
acquired by Vendor during the period of Vendor's engagement by Buyer. Vendor
agrees that any copies or reproductions of any Confidential Information made or
caused to be made by Vendor are the property of Buyer. Vendor agrees to deliver
promptly to Buyer on termination of this Purchase Order, whatever the reason, or
at any time Buyer may so request, all documents, records, Artwork, designs,
data, drawings, flowcharts, listings, models, sketches, apparatus, notebooks,
notes and similar repositories of Confidential Information and any other
documents of a confidential nature belonging to Buyer, including all copies,
summaries, records, descriptions, modifications, drawings or adaptations of such
materials which Vendor may the possess or have under its control.
10. INDEMNIFICATION: Vendor agrees to indemnify and protect Buyer against all
claims, actions, demands losses and liabilities of any kind resulting from: (a)
Vendor's breach of this agreement; (b) infringement of any U.S. or foreign
patent, trademark or intellectual property claims (c) personal injury or
property damage during work on Buyer's premises. Without limiting the foregoing,
Vendor shall maintain public liability and property damage insurance in
reasonable amounts covering the obligations set forth above and required
workman's compensation insurance covering all employees performing this Purchase
Order.
11. WARRANTY:  In addition to all warranties established by statute or common
law or set forth elsewhere in this order, Vendor expressly warrants that all
material or services covered herein shall conform to all specifications,
drawings, samples and descriptions furnished or adopted by Buyer, and shall be
of best quality and fit and sufficient for the purpose for which purchased if
specified hereon, merchantable, of good material and workmanship, free from any
liens and encumbrances, and free from all latent and patent defects. Buyer's
failure to give notice to Vendor of any breach of warranty shall not discharge
Vendor's liability therefor. Without limiting the generality of the foregoing,
Vendor agrees to supply Buyer with copies of operating manuals, drawings,
schematics, diagrams and other information needed for proper maintenance and
repair of applicable purchased material upon Buyer's request therefore, and
Vendor further agrees to be responsible for all defects in design, workmanship
and materials which may become apparent within twelve (12) months of beneficial
occupancy and/or use by the Buyer. These warranties shall run to the Buyer, its
successors, assigns, customers and the users of its products. Buyer's normal
maintenance and repair of applicable purchased material after receipt from
Vendor shall not affect Vendor's warranties and representations stated above.
<PAGE>

                                    EXHIBIT F

           GP'S ESTIMATED FULLY-ABSORBED MANUFACTURING COSTS FOR KBC'S
<PAGE>
                   SUMMARY OF PER TEST COST ESTIMATES FOR BMX
                          MT, CT, AND NG AMP REAGENTS

<TABLE>
<CAPTION>
<S>                                <C>
   MT REAGENT KIT                        TOTAL
     COMPONENT                           COST
---------------------             --------------------
       [***]                             [***]
                                  --------------------
  TOTAL COST FOR MT                      [***]

   CT REAGENT KIT                        TOTAL
     COMPONENT                           COST
---------------------             --------------------
       [***]                             [***]
                                  --------------------
  TOTAL COST FOR CT                      [***]

   NG REAGENT KIT                        TOTAL
     COMPONENT                           COST
---------------------             --------------------
       [***]                             [***]
                                  --------------------
TOTAL COST FOR NG                        [***]
</TABLE>
NOTES:

Costs are based on current lot sizes.
These costs are exclusive of the oligonucleotides for Internal Controls and
Probe Reagents.
These costs do not include the transfer price margin.

*** Certain information on this page has been omitted and filed separately with
    the Commission. Confidential treatment has been requested with respect to
    the omitted portions.

<PAGE>
                                    EXHIBIT G

                       SAMPLE COLLECTION KITS DESCRIPTION
<PAGE>

COLLECTION FOR ENDOCERVICAL SPECIMENS

INSTRUCTIONS FOR CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

[GRAPHIC]

1.   Remove excess mucus from cervical os and surround mucosa using one of the
     swabs provided. DISCARD THE CLEANING SWAB.

2.   Insert second swab from collection kit 1 to 1 1/2 cm into endocervical
     canal.

3.   Rotate swab for 10 to 30 seconds in endocervical canal to ensure adequate
     sampling.

4.   Withdraw swab carefully; avoid any contact with vaginal mucosa.

5.   See Preparation for Transport on reverse side.

COLLECTION FOR MALE URETHRAL SPECIMENS

Patient should not have urinated for at least 1 hour prior to sample collection.

INSTRUCTIONS FOR CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

[GRAPHIC]

1.   Insert swab from collection kit 2 to 4 cm into urethra.

2.   Once inserted, rotate swab gently at least one full rotation using
     sufficient pressure to ensure swab comes into contact with all urethra
     surface. Allow swab to remain inserted for 2 to 3 seconds.

3.   Withdraw swab.

4.   See Preparation for Transport on reverse side.

PREPARATION FOR TRANSPORT

[GRAPHIC]

1.   Insert ONE swab (collection swab only) into the GEN-PROBE transport tube.

2.   Snap off shaft at score line or cut shaft to fit tube.

3.   Cap tube.

4.   For best results, transport tube to the laboratory at 2 degrees C to 25
     degrees C. Store at 2 degrees C to 25 degrees C and test within 7 days of
     collection. If not tested within 7 days, vortex specimen, express swab,
     remove swab, and store tube at minus 20 degrees C to minus 70 degrees C.

NOTE: SPECIMENS COLLECTED WITH THIS SYSTEM CANNOT BE USED FOR CULTURE. ONLY
SWABS SUPPLIED WITH THE GEN-PROBE SPECIMEN COLLECTION SYSTEM SHOULD BE USED FOR
SPECIMEN COLLECTION. CAP TIGHTLY. DO NOT DISCARD LIQUID.

<PAGE>
SPECIMEN COLLECTION AND HANDLING FOR MALE URETHRAL SPECIMENS

  Patient should not have urinated for at least 1 hour prior to sample
  collection.

INSTRUCTIONS FOR CHLAMYDIA TRACHOMATIS (PACE AND AMPLIFIED) AND/OR NEISSERIA
GONORRHOEAE (PACE ONLY)

  1. Insert swab from collection kit 2 to 4 cm into urethra.

  2. Once inserted, gently rotate swab clockwise using sufficient pressure to
     ensure swab comes into contact with all urethral surfaces. Allow swab to
     remain inserted for 2 to 3 seconds.

  3. Withdraw swab.

  4. Prepare swab for transport.

[GRAPHIC]

SPECIMEN COLLECTION AND HANDLING FOR CHLAMYDIA TRACHOMATIS CONJUNCTIVAL
SPECIMENS (PACE ONLY)

  1. If pus or discharge is present, use a sterile Dacron swab (not provided) to
     clean the area. Do not scrape the conjunctiva while cleaning the eye(s).

  2. If both eyes are affected, swab the least affected eye first.

  3. Thoroughly swab the lower then the upper conjunctiva 2 to 3 times each with
     the GEN-PROBE urethral/conjunctival swab.

  4. Prepare swab for transport.

[GRAPHIC]

PREPARATION FOR TRANSPORT

  1. FULLY INSERT ONE SWAB into the GEN-PROBE transport tube.

  2. Snap off shaft at score line or cut shaft to fit tube. Use care to avoid
     splashing of contents.

  3. Cap tube tightly.

  4. For best results, transport tube to the laboratory at 2 degrees to 25
     degrees. Store at 2 (degrees) to 25 (degrees) C and test within 7 days of
     collection.

  5. If not tested within 7 days:

     a. PACE: Vortex specimen, remove swab, and store at -20 (degrees) to -70
        (degrees) C.

     b. AMPLIFIED: Store at -20 (degrees) to -70 (degrees) C.
        DO NOT REMOVE SWAB.

NOTE: SPECIMENS COLLECTED WITH THIS SYSTEM CANNOT BE USED FOR CULTURE. ONLY
GEN-PROBE URETHRAL/CONJUNCTIVAL SWABS SHOULD BE USED FOR SPECIMEN COLLECTION.
<PAGE>
     SPECIMEN COLLECTION AND HANDLING OF
ENDOCERVICAL SPECIMENS FOR C. TRACHOMATIS
(PACE AND AMPLIFIED) AND/OR N. GONORRHOEAE
(PACE ONLY) TESTING

     1.   Remove excess mucus from cervical                 [GRAPHIC]
          os and surrounding mucosa using one          ROTATE CLOCKWISE ONLY
          of the swabs provided. Discard this      TOURNER SEULEMENT DANS LE
          swab.                                  SENS DES AIGUILLES D'UNE MONTRE

     2.   Insert second swab from collection
          kit 1 to 1.5cm into endocervical
          canal.

     3.   Rotate swab clockwise for 10 to 30
          seconds in endocervical canal to
          ensure adequate sampling.

     4.   Withdraw swab carefully; avoid any
          contact with vaginal mucosa.

     5.   Prepare swab for transport.

PREPARATION FOR TRANSPORT

     1.   FULLY INSERT ONE SWAB into the
          GEN-PROBE transport tube.

     2.   Snap off shaft at score line or cut
          shaft to fit tube. Use care to
          avoid splashing of contents.

     3.   Cap tube tightly.

     4.   For best results, transport tube to
          the laboratory at 2(degrees) to
          25(degrees)C. Store at 2(degrees)
          to 25(degrees)C and test within
          7 days of collection.

     5.   If not tested within 7 days:

          a.  PACE: Vortex specimen, remove
          swab, and store at -20(degrees) to
          -70(degrees)C.

          b.   AMPLIFIED:     Store at
          -20(degrees) to -70(degrees)C.
          DO NOT REMOVE SWAB.

     NOTE: SPECIMENS COLLECTED WITH THIS
SYSTEM CANNOT BE USED FOR CULTURE. ONLY SWABS
WITH THE GEN-PROBE SPECIMEN COLLECTION SYSTEM
SHOULD BE USED FOR SPECIMEN COLLECTION.
<PAGE>
                                    EXHIBIT H

                  EXCERPTS OF STANFORD AND TEKNIKA AGREEMENTS

<PAGE>

ADDITIONAL CLAUSES RELATING TO THE STANFORD AGREEMENT AND THE TEKNIKA AGREEMENT

STANFORD LICENSE

     The Stanford Agreement sets forth the following terms and conditions
relating to required provisions in any sublicense and to the continuation of
sublicenses following termination of the Stanford Agreement.

     4.3.2 Any such sublicense shall also expressly include the provisions of
Articles 7, 8, and 9 for the benefit of STANFORD.

     4.3.3 Upon termination of this Agreement for any cause, any sublicense
granted hereunder shall continue with STANFORD provided the sublicensee agrees
to thereafter assume the obligations of GEN-PROBE insofar as they correspond to
the scope of the sublicense.

7.   REPORTS, PAYMENTS, AND ACCOUNTING

     7.1 Quarterly Royalty Payment and Report. GEN-PROBE shall make written
reports and royalty payments to STANFORD within ninety (90) days after the end
of each calendar quarter. This report shall state the number, description, and
aggregate Net Sales of Licensed Product(s) during such completed calendar
quarter, and resulting calculation pursuant to Paragraph 6.2 of earned royalty
payment due STANFORD for such completed calendar quarter. Concurrent with the
making of each such report, GEN-PROBE shall include payment due STANFORD of
royalties for the calendar quarter covered by such report.

     7.2 Accounting. GEN-PROBE agrees to keep records for a period of three (3)
years showing the manufacturing, sales, use, and other disposition of products
sold or otherwise disposed of under the license herein granted in sufficient
detail to enable the royalties payable hereunder by GEN-PROBE to be determined,
and further agrees to permit its books and records to be examined to the extent
necessary to verify reports provided for in Paragraph 7.1 by an independent
certified public accountant, provided that such audits occur no more than one
(1) time per calendar year and provided further that accountant shall report to
STANFORD only errors regarding calculation of royalties. Such examination is to
be made by STANFORD, at the expense of STANFORD, except in the event that the
results of the audit reveal a discrepancy in GEN-PROBE's favor of ten percent
(10%) or more, then the audit fees shall be paid by GEN-PROBE.

                                       1
<PAGE>
8.   WARRANTY AND NEGATION OF WARRANTIES

     8.1  Nothing in this Agreement is or shall be construed as:

     (a)  A warranty or representation by STANFORD as to the validity or scope
of any Licensed Patent(s);

     (b)  A warranty or representation that anything made, used, sold, or
otherwise disposed of under any license granted in this Agreement is or will be
free from/of patents, copyrights, and other rights of third parties;

     (c)  An obligation to bring or prosecute actions or suits against third
parties for infringement, except to the extent and in the circumstances
described in Article 12; or

     (d)  Granting by implication, estoppel, or otherwise any licenses under
patents of STANFORD or other persons other than Licensed Patent(s), regardless
of whether such patents are dominant or subordinate to any Licensed Patent(s).

     8.2  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, STANFORD MAKES NO
REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE LICENSED PRODUCT(S)
WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF THIRD
PARTIES.

     9.   INDEMNITY

     9.1 GEN-PROBE agrees to indemnify, hold harmless, and defend STANFORD and
its trustees, officers, employees, students, and agents against any and all
claims for death, illness, personal injury, property damage, and improper
business practices arising out of the manufacture, use, sale, or other
disposition of Invention, Licensed Patent(s), or Licensed Product(s) by
GEN-PROBE, its sublicenses or their customers.

     9.2  GEN-PROBE shall at all times comply, through insurance or
self-insurance, with all statutory workers' compensation and employers'
liability requirements covering any and all employees with respect to
activities performed under this Agreement.

     9.3  GEN-PROBE shall maintain, beginning on the first day GEN-PROBE or any
GEN-PROBE sublicensee ships a therapeutics product manufactured by the licensed
process, commercial general liability insurance, including products liability
insurance, with minimum limits of liability of $5 million with reputable and

                                       2
<PAGE>
financially secure insurance carrier(s) to cover the activities of GEN-PROBE and
its sublicensee(s). Any and all such policies of insurance described in the
previous sentence shall include as additional named insureds STANFORD, Stanford
Health Services, their trustees, diretors, officers, employees, students and
agents, and shall provide that such policies may not, without 30 days prior
written notice to STANFORD, be canceled or changed to materially adversely
affect any such additional named insured's coverage. Such insurance shall be
written to cover liability of such additional named insureds incurred beginning
on the first day GEN-PROBE or any GEN-PROBE sublicensee ships a therapeutics
product.

Teknika Agreement

     The Teknika Agreement sets forth the following terms and conditions
relating to rights of Gen-Probe's Licensees should a breach by Gen-Probe
terminate its rights under the Teknika Agreement.

     10.3  Upon termination of this Agreement, as permitted by Section 10.2, the
non-breaching party shall grant direct immunity from legal action to Licensees
of the breaching party, under the terms and conditions set forth in this
Agreement, provided that:

     (a)   the non-breaching party shall have received express written notice of
the license granted to such Licensee prior to the effective termination date of
this Agreement;

     (b)   the Licensee expressly agreed in writing on or before the ninetieth
(90th) day prior to the effective termination date of this Agreement to be bound
by the terms and conditions of this Agreement.

*** Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3

<PAGE>
                                   EXHIBIT E

                   TRANSCRIPTION-BASED AMPLIFICATION VERSIONS

     "GEN-PROBE Version" shall mean transcription-based nucleic acid
amplification using reverse transcriptase, RNA polymerase and [***] wherein

          (a)  the reverse transcriptase and RNase H activities are provided by
a [***];

          (b)  said protein has a minimal reverse transcriptase activity of
[***] (where the unit definition and assay conditions are equivalent to those
set forth below); and

          (c)  the amplification reaction is performed at a [***].

    "TEKNIKA Version" shall mean transcription-based nucleic acid amplification
using reverse transcriptase, RNA polymerase and [***], wherein

          (a)  [***]

          (b)  [***] and

          (c)  the amplification reaction is performed at [***].

ENZYME ASSAYS

[***]

[***]

[***]

[***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       1

<PAGE>

[***]

Equivalent unit definitions and assay conditions may be substituted as long as
they produce results that may be quantitatively converted by established valid
procedures (e.g., multiplication by a conversion factor or by reference to a
standard curve) to the assay conditions and unit definitions set forth above.

For example, [***]

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       2

<PAGE>
[***]

Data supporting equivalence of any substitutions must be made available for
inspection as set forth in Section 3.3 of this Agreement.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                                       3<PAGE>

CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

                                                                   EXHIBIT 10.14

                     DISTRIBUTORSHIP ARRANGEMENTS AGREEMENT

     This Distributorship Arrangements Agreement (the "Agreement") is entered
into this 2nd day of May, 1997, by and between Gen-Probe Incorporated, a
Delaware corporation, with its principal place of business located at 9880
Campus Point Drive, San Diego, California 92121, USA ("GEN-PROBE"), and
bioMerieux S.A., a French corporation, having its principal place of business
located at Chemin de l'Orme, 69280 Marcy L'Etoile, France ("BIOMERIEUX").

RECITALS

     A.   BIOMERIEUX and GEN-PROBE have entered into a Distribution Agreement
of even date herewith, pursuant to which BIOMERIEUX has agreed to act as
exclusive distributor for the sale of certain GEN-PROBE products in certain
specified countries.

     B.   To permit BIOMERIEUX to assume responsibilities as exclusive
distributor for GEN-PROBE, GEN-PROBE will undertake negotiations to terminate
its existing distribution agreements relating to such countries in an orderly
fashion consistent with all legal obligations toward existing distributors; and

     C.   BIOMERIEUX will assist GEN-PROBE in connection with such negotiated
arrangements, by providing a Termination Allocation on a country by country
basis as provided hereafter.

AGREEMENT

     Now, therefore, the parties hereto agree as follows:

          1.        Definitions. For the purposes of this Agreement, the terms

set forth below shall have the following meanings. Capitalized terms not
otherwise defined herein shall have the meanings ascribed to them in the
Distribution Agreement.

               1.1  "Phase I Countries" shall mean France, Italy, Malta,
Germany, Spain, Portugal, Austria, Switzerland, Liechtenstein, United Kingdom,
Australia, Ireland, Netherlands, Belgium and Luxembourg.

               1.2  "Phase II Countries" shall mean South Korea, New Zealand,
Greece, Singapore and Iceland.

               1.3  "Phase III Countries" shall mean any countries not listed
as Phase I Countries or Phase II Countries, but excluding the (i) United
States, Canada and Japan and (ii)

<PAGE>
the Peoples Republic of China, Hong Kong, Taiwan, Philippines, Malaysia,
Indonesia, Singapore and Thailand. It is recognized that the parties may in the
future consider the possible inclusion of one or more of the countries listed in
sub-clause (ii) of the preceding sentence within the Phase III Countries,
provided that any such inclusion shall require a written amendment of this
Agreement and, provided further, that neither party shall be under any
obligation whatsoever to agree to any such inclusion or to execute any such
amendment. If GEN-PROBE elects to appoint an exclusive distributor other than
Chugai Pharmaceuticals or an Affiliate of Chugai Pharmaceuticals in any of the
countries listed in sub-clause (ii) of the next preceding sentence, GEN-PROBE
shall give BIOMERIEUX priority consideration for such appointment.

          1.4  "Termination Allocation" shall mean (i) for each Phase I Country
and on a country-by-country basis, up to the maximum amount of [***] which
BIOMERIEUX will pay to GEN-PROBE in respect of payments made by GEN-PROBE (other
than the amounts described in Section 2.1(b) below) to terminate GEN-PROBE's
present distributors, as calculated in accordance with Exhibit A hereto, and
(ii) for Phase II Countries and Phase III Countries, the aggregate amount of
[***] to be paid in respect of the termination of existing distributors in such
other countries as the parties shall mutually agree. The total of the foregoing
sums is hereinafter referred to a the "Termination Amount".

          1.5  "Territory" shall mean such of the Phase I Countries, Phase II
Countries and Phase III Countries in which all existing distribution agreements
with third parties relating to the distribution of GEN-PROBE's Products in such
countries as have been designated by GEN-PROBE on Exhibit A have been terminated
by mutual agreement of GEN-PROBE and such third parties in such manner as to
permit BIOMERIEUX to undertake its responsibilities hereunder, it being agreed
that (i) no such country shall be deemed to be included within the Territory
unless and until all the designated distribution agreements for said country
have been so terminated, (ii) no country identified as a Phase II Country shall
be deemed to be included in the Territory unless and until all of the Phase I
Countries have become part of the Territory (except that the foregoing
requirement may be waived by BIOMERIEUX in its sole discretion in respect of any
of the Phase I Countries (although any such waiver shall not affect GEN-PROBE's
obligation to effect such terminations)), and (iii) no country identified as a
Phase III Country shall be deemed to be included in the Territory unless so
designated by mutual written agreement of the parties hereto.

     2.   Termination of Existing Arrangements.

          2.1  Third Party Distributors.

               (a) Attached hereto as Exhibit B is a list of all third party
distributors currently distributing GEN-PROBE's Products within the Phase I
Countries, the Phase II Countries and the Phase III Countries as of the date
hereof ("Existing Distributors"). GEN-PROBE agrees to use all reasonable efforts
to terminate its distribution agreements in Phase I Countries with each of said
distributors as promptly as possible, it being agreed that such efforts shall be
an ongoing requirement during a reasonable period until success is achieved in
each

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -2-

<PAGE>
such country but shall not be deemed to require aggregate payments by GEN-PROBE
to any such third parties in any country of total amounts in excess of the
Termination Allocation for such country, increased by the excess, if any, of the
amount, if any, by which the Termination Allocation for Phase I Countries as to
which all the designated distribution agreements have been previously terminated
by GEN-PROBE exceeded the amount actually paid to the terminated distributors
therein. With respect to each of the Phase I Countries, the Termination
Allocation (adjusted as aforesaid) shall be paid by BIOMERIEUX to GEN-PROBE
within five days of certification by GEN-PROBE that one or more agreements have
been reached for the termination of all the distribution agreements with respect
to such country or (in the case of the Benelux countries, the Benelux region to
be considered as a unit), subject only to the payment of termination amounts to
the Existing Distributor(s) not exceeding the amounts described above. The
Termination Allocation for the Phase II Countries and the Phase III Countries
shall be paid as the parties mutually agree.

               (b)  It is understood and agreed that GEN-PROBE may seek to
repurchase the inventory of systems and reagents and the installed base of
systems from each terminated distributor. GEN-PROBE undertakes to use
reasonable efforts to reacquire the inventory of systems and reagents and the
installed base of systems from each terminated distributor on the terms and
conditions set forth in Exhibit C. To the extent GEN-PROBE is able to effect
such repurchases in accordance with Exhibit C, BIOMERIEUX shall be obligated,
upon completion of an appropriate audit, to purchase such inventory and systems
at a price equal to the amount so paid by GEN-PROBE to the applicable
terminated distributor for the relevant items. In each case, GEN-PROBE and
BIOMERIEUX shall cooperate with each other in any reasonable arrangements
designed to minimize any sales, use, value added and other taxes applicable to
such transactions, including, by way of example, through the assignment by
GEN-PROBE to BIOMERIEUX of its right to purchase such inventory. GEN-PROBE
shall use best efforts to procure the transfer to BIOMERIEUX of any and all
product registrations obtained by the prior distributors.

          2.2  Transfer of French Assets and Operations.  Notwithstanding
anything to the contrary in Section 2.1, GEN-PROBE's existing arrangements in
France shall be terminated and operations transferred to BIOMERIEUX as provided
in Exhibit D hereto, which shall constitute an integral part of this Agreement.

          2.3  GEN-PROBE's Obligation of Good Faith Compliance. All termination
negotiations by GEN-PROBE with Existing Distributors throughout the Territory
shall be carried out by GEN-PROBE in good faith consistent with applicable
legal requirements. BIOMERIEUX will not be called on to participate in any such
negotiations or to pay any of the costs thereof except as otherwise provided
herein.

     3.   Termination of Exclusivity.

     In the event that BIOMERIEUX fails to achieve the Minimum Purchase
Commitment for any Performance Period and GEN-PROBE, pursuant to Section 3.3 of
the

                                      -3-

<PAGE>
Distribution Agreement, terminates the exclusivity of the distribution rights
granted pursuant to Section 2.1 thereof, GEN-PROBE shall no longer be required,
from and after the effective date of exercise of such right, to terminate any
remaining distribution agreements of Existing Distributors hereunder.

     4.   Termination of Distribution Agreement.

     This Agreement shall remain in effect until the expiration of the
Distribution Agreement. If GEN-PROBE shall terminate the Distribution Agreement
in accordance with the provisions thereof, GEN-PROBE shall have the right to
terminate this Agreement at the time of such termination. In addition, either
party may terminate this Agreement on written notice given to the other party
prior to the scheduled expiration of the Term in the event of a material breach
of any of the terms hereof or of the Distribution Agreement (including any
payment terms) by the other party not cured within sixty (60) days (thirty (30)
days for an obligation to pay monies unless the same is contested in good faith,
in which case, to avert default, the paying party may deposit the disputed
amount with a third-party escrow agent pending resolution of such dispute and
interest shall be payable on all disputed amounts determined to be payable at an
annual rate of two percentage points above the prime rate from time to time
quoted by Bank of America at its principal office in San Francisco, California,
with changes in such prime rate to be effective as of the date of such change)
from and after written notice of such breach is given by the terminating party.
Termination of this Agreement shall not release either party from any liability
or obligation arising prior to the date of such expiration or termination.

     5.   Application of Provisions.

     The provisions set forth in Section 10 (Confidential Information), Section
12 (Relationship of the Parties), Section 14 (Termination) (other than Section
14.4), Section 15 (Indemnification), Section 17 (Notices) and Section 19
(Miscellaneous) (other than Section 19.5) of the Distribution Agreement shall
apply, mutatis mutandis to this Agreement as if set forth here in full and the
"Agreement" as referred to in such Sections shall be deemed for these purposes
to be this Agreement.

AGREED TO AND ACCEPTED BY

GEN-PROBE INCORPORATED                       BIOMERIEUX, S.A.

By: /s/ Daniel L. Kacian                     By: /s/ Philippe A. Archinard
   ----------------------------------           -----------------------------
   Name:   Daniel L. Kacian                     Name:   Philippe A. Archinard
   Title:  Senior Vice President and            Title:  Authorized Signatory
           Chief Scientific Officer

                                   - 4 -
<PAGE>
                         EXHIBIT A

                    Termination Allocation
                    ----------------------

     1.   Based upon sales information provided by GEN-PROBE, the parties have
estimated that the Termination Allocation for each Phase I Country shall be as
set forth below. The parties shall reasonably consult with each other as to the
adequacy of such estimated allocations based upon actual negotiations with the
terminated distributors.

<Table>
<S>                           <C>
Australia                      [***]
Germany                        [***]
Ireland                        [***]
Italy/Malta                    [***]
Austria                        [***]
United Kingdom                 [***]
Spain/Portugal                 [***]
Switzerland/Liechtenstein      [***]
Benelux                        [***]
                              --------
                               [***]
                              ========
</TABLE>

     2.   In addition, BIOMERIEUX shall reimburse GEN-PROBE for up to [***]
of termination payments made to expedite the termination of Existing
Distributors in Phase II Countries and Phase III Countries, subject to mutual
agreement of the parties with respect to such payments. GEN-PROBE shall
reasonably consult with BIOMERIEUX concerning such terminations in the Phase II
Countries so as to afford BIOMERIEUX a reasonable opportunity to commence
distribution operations in such countries.

***Certain information on this page has been omitted and filed separately with
the Commission. Confidential treatment has been requested with respect to the
omitted portions.

                              - 5 -
<PAGE>
                         EXHIBIT B

                    List of Existing Distributors

                             - 6 -
<PAGE>
GEN-PROBE                  International Distributors

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------
                                              GEN-PROBE EUROPEAN PERSONNEL
------------------------------------------------------------------------------------------------------------------------
<S>                           <C>                      <C>                           <C>
Filip Rosseel                                          Marc Dubucq, Ph.D.
European Region Sales &       Ofc & Mobile             European Region Sales &       Office Phone: 32-10-659896
Marketing Manager             Phone: 39-335-281895     Marketing Manager             Fax:      32-10-659710
Piazza Baronino 10            Fax:   39-142-454671     7, rue des pres               Mobile:   32-75-473587
15033 Casale Monferrato  (AL) Private                  B-1435 CORBAIS                Private:  32-10-650979
ITALY                         Phone: 39-142-454505     BELGIUM                       E-mail:   @ Compuserve 100306,3005

Southern European Sales & Support Territory:           Northern European Sales & Support Territory:
     Austria, Italy, Spain, Switzerland, Greece,            Germany, Netherlands, United Kingdom,
     South Africa and Israel                                Denmark, Finland, Norway and Sweden
Technical Support (Only) Territory: France
------------------------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>
------------------------------------------------------------------------------------------------------------------------
                                                    GEN-PROBE FRANCE
------------------------------------------------------------------------------------------------------------------------
<S>                                                   <C>
Vecteur Sud  011-33-1-45-75-424                        Martine Roux, Director of Sales/Marketing
70-86 Avenue de la Republique                          Sophie Grillere, Sales Manager
92325 Chatillon Cedex                                  Christophe Desbuquoy, Sales Engineer
FRANCE                                                 Angela Ribeiro, Sales Engineer
Phone:  33-1-41 17 48 98                               Annie Malpart, Commercial Assistant
Fax:    33-1-41 17 48 90                               Olivier Lafrique, Warehouseman
</TABLE>

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------------
                  COMPANY                                                 CONTACT(S)/TERRITORY NOTES
-------------------------------------------------------------------------------------------------------------------------
<S>                                                    <C>                                         <C>
BI-MED LTD
148 Beauvale Park                                      Peter JF. Donohoe, Sales Manager
Beaumont, Dublin 5
IRELAND
Phone/Fax: 353-1-8314762
-------------------------------------------------------------------------------------------------------------------------
BIO MEDIQ DPC PTY LTD.                                                                               CUSTOMER # 0090760000
-------------------------------------------------------------------------------------------------------------------------
P.O. Box 106                                           Kevin Walsh, President
Doncaster, Victoria 3108                               John Sabatino, Nat'l Product & Development Mgr.
Australia                                              Actual Location: 1 Williamsons Rd., Doncaster, Victoria 3108
Phone:  61-39-840-1800
Fax:    61-39-840-2767
-------------------------------------------------------------------------------------------------------------------------
BUHLMANN LABORATORIES AG                                                                            CUSTOMER # 0090690000
-------------------------------------------------------------------------------------------------------------------------
Postfach                                               Dr. Roland P. Buhlmann, President
CH-4123 ALLSCHWIL 1                                    Regis Vuillemin, Vice-President
Switzerland
Phone:  41-61-4812828
Fax:    41-61-4812868
-------------------------------------------------------------------------------------------------------------------------
CHOONGWAE PHARMA CORPORATION                                                                        CUSTOMER # 0090930000
-------------------------------------------------------------------------------------------------------------------------
698 Shindaebang-Dong                                   Chang-Ryul, Chu, General Manager
Dongjak-ku, Seoul 158-757                              In-Je Hwang, Supervisor, Science & Information
Republic of Korea                                           Sect, Diagnostics Reagents Department
Phone:  82-2-840-6632
Fax:    82-2-843-7697
-------------------------------------------------------------------------------------------------------------------------
CHUGAI PHARMACEUTICAL CO., LTD.                                                                     CUSTOMER # 0090480000
-------------------------------------------------------------------------------------------------------------------------
21-1, Nishi-shinjuku 1-chome                           Jiro Hada, General Manager, Diagnostics Division
Shinjuku-ku Tokyo, 160, Japan                          Kiyoshige Wakabayashi, Ph.D., Deputy General Mgr.,
Phone:  81-3-3348-7950                                      Diagnostics Division
Fax:    81-3-3348-8033 (Diagnostics Division)          Toshinobu Ishibashi, Mgr., Product Dev't, Diag. Division
-------------------------------------------------------------------------------------------------------------------------
CPEI (CENTRAL DE PRODUCTOS ENZIMILICOS E IMUNOLOGICOS LTD.)                                          CUSTOMER # 009120000
-------------------------------------------------------------------------------------------------------------------------
Run Martinico Prodo                                    Morton Scheinberg, M.D.Ph.D.F.A.C.P.
??-12? ???? cj 125
01224-010 - Vila Buarque - Sao Paulo BRAZIL
Phone:  55-11-220-1811
Fax:    55-11-223-9972
</TABLE>

<PAGE>
[GEN-PROBE LOGO]             INTERNATIONAL DISTRIBUTORS

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
                         COMPANY                                                        CONTACT(S)/TERRITORY NOTES
<S>                                                                   <C>
------------------------------------------------------------------------------------------------------------------------------------
DIAGNOSTIC BIOTECHNOLOGY CO., LTD.                                                                            CUSTOMER #: 0091060000
------------------------------------------------------------------------------------------------------------------------------------
Biopex Building, 749/12 Soi Wat-Channai                               Vitoon Vonghangool, Executive Director
Off Soi Pradoo, Sathupradit Road                                             Direct Line: 662-5123904
Bankphongphang, Yannawa                                               Mr. Suwan Ponsunk
Bangkok, 10120 Thailand                                               Mr. Meesak Pitanchote
Phone: 662-284-0309
Fax: 662-295-3632
------------------------------------------------------------------------------------------------------------------------------------
DIAGNOSTIC GRIFOLS, S.A.                                                                                      CUSTOMER #: 0090440000
------------------------------------------------------------------------------------------------------------------------------------
Ctrs. Nacional                                                        Oriol Dunach, President, Diagnostics
Km. 21 - Pol. Sector Autopista                                        Agustin Diaz-Prieto, Laboratory Division Manager
08150 Parets del Valles                                               Carlos Restrepo, Product Manager, Laboratory Division
Barcelona, Spain
Phone: 34-3-5710200                                                   Spain & Portugal
Fax: 34-3-5731132
------------------------------------------------------------------------------------------------------------------------------------
DPC NEDERLAND                                                                                                 CUSTOMER #: 0090680000
------------------------------------------------------------------------------------------------------------------------------------
Van Golsteinlaan 26                                                   Nico Arnold, President
NL-7339 GT Apeldoorn-Ugchelen                                         Dr. Hans IJpelaar, Product Manager
The Netherlands                                                                Phone: 31-76593-3442, Fax: 31-76593-4066
Phone: 31-555-413355                                                  DPC Belgium, Kerstraat 224
Fax: 31-555-426279                                                    B-1851 Humbeek, Belgium
                                                                      Phone: 32-2-2700030, Fax: 32-2-2700737
------------------------------------------------------------------------------------------------------------------------------------
DICIPA (DISTRIBUTED CIENTIFICO PALLACH, S.A. DE C.V.)                                                         CUSTOMER #: 0091160000
------------------------------------------------------------------------------------------------------------------------------------
Av. Nuevo Leon 125F 06140                                             Francisco Ernesto Pallach, National Sales Manager
Mexico, D.F.                                                          Alejandra Posadas L. Especialista Linea Gen-Probe
Phone: 525-211-0402
       525-286-7285
Fax:   525-286-6053
------------------------------------------------------------------------------------------------------------------------------------
DPC BIERMANN GmbH                                                                                             CUSTOMER #: 0090640000
------------------------------------------------------------------------------------------------------------------------------------
Hohestrasse, 4-6          PLEASE NOTE DIFFERENT                       Dr. Willi Tillmann, Managing Director
D-61231 Bad Nauheim       ZIP CODE FOR P.O. BOX                                 (Fax: 49-6032-809444)
Germany                   ADDRESS:                                    Hermann Steppich, Group Product Manager, DNA
Phone: 49-6032-994-00     P.O. Box 1206                               Dr. Peter Zwerenz, Product Manager
Fax:   49-6032-994-200    D-61212 Bad Nauheim                                   (Phone: 49-6032-809419)
                          Germany                                     Ralf Dostatni, Product Manager
------------------------------------------------------------------------------------------------------------------------------------
DPC SKAFTE AB                                                                                                 CUSTOMER #: 0090730000
------------------------------------------------------------------------------------------------------------------------------------
Kaerragatan 8,                                                        Harald Skafte, President
S-431 53 Molndal, Sweden                                              Kerstin Andersson, Product Manager,
Phone: 46-31-275195                                                           Phone/Fax: 46-18-403445
Fax:   46-31-871844
------------------------------------------------------------------------------------------------------------------------------------
EPIGNOST Ges.m.b.H.                                                                                           CUSTOMER #: 0090660000
------------------------------------------------------------------------------------------------------------------------------------
Bannerstrasse, 10                                                     Rudolph Hellmayr, Sales Dir. (phone 011-43-732-84236,
A-4020 Linz                                                           fax 011-43-732-84295, Linz apt. 011-43-732-235-2883,
Austria                                                               home 011-43-1-804-2905)
Phone: 43-732-8008131                                                 Mr. Jorg Mayrhofer, President (011-43-732-278401-2004)
       43-732-84236                                                   Mr. Haas (011-43-732-278401/243)
Fax:   43-732-81431-15                                                Sylvia Hauseder, Sales/Product Manager
------------------------------------------------------------------------------------------------------------------------------------
EUROGENETICS UK LTD                                                                                             CUSTOMER #0090500000
------------------------------------------------------------------------------------------------------------------------------------
Unit S. Kingsway Business Pk       Eurogenetics NV                    Bruce Morris, Director
Oldfield Road, Hampton             Industrie Park 24                  James Lee, Product Manager (44-113-230-7282)
Middlesex TW 12 2HD                Industrie zone West                Tina Humm, Marketing Assistant
Great Britain                      B-3980 Tessenderloo, Belgium       Dr. Freddy Lecock (Tech. Support) Located in Belgium
Phone: 44-181-296-8800             Phone: 32-13-668830
Fax:   44-181-296-9039             Fax:   32-13-672494
------------------------------------------------------------------------------------------------------------------------------------

</Table>
<PAGE>
[LOGO] Gen-Probe             International Distributors

<Table>
<S>                                                   <C>
====================================================================================================
COMPANY                                                 CONTACT(S)/TERRITORY NOTES
====================================================================================================
EZRA BROTHERS                                                                 Customer #: 0091180000
----------------------------------------------------------------------------------------------------
4. Mustafa Bldg, Sir P.M. Road, P.O. Box 633     Jagadish Shah, Marketing Manager
Bombay 400 001, INDIA                            K. Narayan, Technical Advisor
Phone: 91-22-2660975
Fax:   91-22-2665407 or 3738830
====================================================================================================
FIRST MONITOR (UK) LIMITED                                                    Customer #: 0091040000
----------------------------------------------------------------------------------------------------
Welyen Garden City, P.O. Box 151                 Dr. Magid Hafes, President
Hertfordshire AL8 6HG, United Kingdom            Eddy Velthuis, Technical Support Manager
Phone: 44-1707-256585                            John H. Back, Customer Support Manager
Fax:   44-1707-256796                            Richard J. Walker, Sales Manager
Note:  Advanced Diagnostic Systems (ADS)
       is a division of First Monitor.           Middle Eastern countries except for Israel & Turkey
====================================================================================================
GRUPO GRIFOLS ARGENTINA                                                       Customer #: 0090440001
----------------------------------------------------------------------------------------------------
Ruta 202 n* 3462                                 Mr. Alberto Grifols
Don Torcuato 1611
Buenos Aires, Argentina
Phone: 54-1-7482798
Fax:   51-1-7415535
====================================================================================================
GRUPO GRIFOLS CHILE                                                           Customer #: 0090440002
----------------------------------------------------------------------------------------------------
C/Zanartu, 2245                                  Mrs. Cecilia Lazcano
Comuna de Nunoa
Santiago de Chile
Phone: 56-2-2396241
       56-2-2396476
       56-2-2394659
Fax:   56-2-2394554
====================================================================================================
IMMUNO DIAGNOSTIC OY                                                          Customer #: 0090340000
----------------------------------------------------------------------------------------------------
Turuntie 8 L 1                                   Pentti Lehtonen, President
Box 342                                          Tuula Palmen
SF-13131 Hameenlinne
Finland
Phone: 358-17-6822758
Fax:   358-17-6822039
====================================================================================================
INNOVATIVE BIOTECH PTE LTD.                                                   Customer #: 0091030000
----------------------------------------------------------------------------------------------------
Billing Address:        Shipping Address:        Dr. Khong Peck Wah, President & Chief Executive
----------------        -----------------                Officer
77 Ayer Rajah Cresent   12 Science Park Drive    Omar Hashim, Sales Manager
#03-04 Ayer Rajan       #02-03 The Mendel
Industrial Estate       Singapore Science Park
Singapore 0513          Singapore 0511           Singapore, Malaysia & Brunei
Phone: 65-779-1919      Phone: 65-779-1919
Fax:   65-779-1112      Fax:   65-779-1112
====================================================================================================
INTERDIAGNOSTICS S.A.                                                         Customer #: 0090830000
----------------------------------------------------------------------------------------------------
Current
Distributor same
one BMX uses
====================================================================================================
XINGO DIAGNOSTIKA Aps                                                         Customer #: 0030212000
----------------------------------------------------------------------------------------------------
Raesvaenge 1                                   Kaj Kingo, President
DK-4720 Prcesto
Denmark
Phone: 45-55-993050                            Denmark, Iceland & Faroe Islands
Fax:   45-55-993048
====================================================================================================
</Table>
<PAGE>
GEN-PROBE                  INTERNATIONAL DISTRIBUTORS

<Table>
<Caption>
------------------------------------------------------------------------------------------------------------------------------------
                         COMPANY                                                        CONTACT(S)/TERRITORY NOTES
<S>                                                                   <C>
------------------------------------------------------------------------------------------------------------------------------------
KJEMI-DIAGNOSTIKK AS                                                                                          CUSTOMER #: 0090770000
------------------------------------------------------------------------------------------------------------------------------------
Tegelverksveien 7                                                     Mr. Ivar Bodin, Marketing Manager
N-3010- Drammen                                                       Mrs. Marit Sorsveen, Product Manager
Norway
Phone: 47-32-848700
Fax:   47-32-848710
------------------------------------------------------------------------------------------------------------------------------------
LONG CHAIN INTERNATIONAL CORP.                                                                                CUSTOMER #: 0090920000
------------------------------------------------------------------------------------------------------------------------------------
3F, 64 T'A Cheng Street                                               Frank Huang, Managing Director
Taipei, Taiwan                                                        Mark Yeh, Marketing Manager
Republic of China                                                     David Sheu, Marketing Assistant
Phone: 886-2 552-2605
Fax: 886-2-552-5461
------------------------------------------------------------------------------------------------------------------------------------
MED BIO ENTERPRISES LTD.                                                                                      CUSTOMER #: 0090900000
------------------------------------------------------------------------------------------------------------------------------------
Postal Address:               Delivery Address:                       Warren Dellow, Managing Director
P.O. Box 11-016 Sockburn      46 Halwyn Drive
Christchurch,                 Hornby
New Zealand                   Christchurch
Phone: 64-3-3494950           New Zealand
Fax:   64-3-3494424
------------------------------------------------------------------------------------------------------------------------------------
MEDICAL SYSTEMS, S.P.A.                                                                                       CUSTOMER #: 0090540000
------------------------------------------------------------------------------------------------------------------------------------
Via Rio Torbido, 40                                                   Marco Pater, CEO, President
I-16165 Genova Struppa                                                Rinaldo Risso, Vice President/General Manager
Italy                                                                 Tiziana Chiesa, Product Manager
Phone: 39-10-83401                                                    Dot. Fabio Lorenzotti, Director, Biodivision
Fax:   39-10-802257-Scientific Dept.
       39-10-804363-Warehouse (internat'l shipments)
       39-10-808007-Marketing
       39-10-808045-Finance
------------------------------------------------------------------------------------------------------------------------------------
PHARMATRADE LTD.                                                                                              CUSTOMER #: 0091050000
------------------------------------------------------------------------------------------------------------------------------------
3 Bazel Street                                                        Isaac Eskenazi, Director
P.O. Box 3962                                                         Harel Toder, Sales Manager
Petach-Tikvah 49126                                                   Avi Lee, Product Manager
Israel
Phone: 972-3-9230048                                                  Israel, including West Bank, Gaza, and East Jerusalem
Fax:   972-3-9232549
------------------------------------------------------------------------------------------------------------------------------------
RIDGE DIAGNOSTICS                                                                                             CUSTOMER #: 0091170000
------------------------------------------------------------------------------------------------------------------------------------
P.O. BOX 383                                                          Bernard Vorster, Director
Fourways                                                              Christopher Helme, Director
2055 South Africa
Phone: 27-11-465-1430 or 27-11-465-1431                               South Africa, Lesotho, Swaziland, Botswana, Nambia,
Fax:   27-11-465-1454                                                 Zimbabwe and Mozambique
------------------------------------------------------------------------------------------------------------------------------------
WENLIN COMPANY                                                                                                CUSTOMER #: 0091080000
------------------------------------------------------------------------------------------------------------------------------------
Room 302-3 Lap Fai Building                                           Yvonne Chan, General Manager
6-8 Pottinger Street
Central District, Hong Kong
Phone: 852-2521-2439
Fax:   852-2526-7053
------------------------------------------------------------------------------------------------------------------------------------
</Table>

Company Proprietary                Page 4 of 4                   April 29, 1996
<PAGE>
                                   EXHIBIT C

                          Certain Terms and Conditions

     GEN-PROBE shall endeavor to acquire inventory and installed systems from
the Existing Distributors in the applicable countries on the following basis:

     A. Inventories of Reagents - on the basis of final cost paid by the
Existing Distributor for the reagents ("Landed Cost Basis"). GEN-PROBE shall
seek to acquire such inventories subject to their conformity (after audit) with
BIOMERIEUX quality standards and provided that they have a remaining shelf life
of at least six months.

     B. Inventories of Systems and System Parts - on a Landed Cost Basis.
GEN-PROBE shall seek to acquire such inventories that are in working order and
at the time of purchase appear in GEN-PROBE's latest catalogue with respect to
the territory involved (i.e., are marketable in the applicable territory).

     C. Installed Systems - on the basis set forth below for such systems
installed during the specified period,

Period from Installation to Reacquisition       Reacquisition Price/Basis
-----------------------------------------       -------------------------
          less than 1 year                      [***] Landed Cost Basis*
          from 1 to 2 years                     [***] Landed Cost Basis*
          from 2 to 3 years                     [***] Landed Cost Basis*
          more than 3 years                     [***] Landed Cost Basis*

--------------
*    But only if systems are still being used by the clients for whom they are
installed, and are still generating sales by way of reagent supply.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.
<PAGE>

                                   EXHIBIT D

                    Transfer Of French Assets and Operations
                    ----------------------------------------

I.   Transfer Of Certain Assets and Operations of Gen-Probe France, S.A.

     In connection with conclusion of the accompanying Distributorship
Arrangements Agreement between Gen-Probe Incorporated ("GEN-PROBE") and
bioMerieux S.A. ("BIOMERIEUX"), GEN-PROBE will cause its wholly owned French
subsidiary, GEN-PROBE France, S.A. ("GP France"), to make the following
assignments and transfers to BIOMERIEUX and BIOMERIEUX will accept the same.

     A.   Assignment of Agreements.

          1.   All rights and obligations of GP France under the lease agreement
               dated May 12, 1993, as amended to date, between GP France and
               Vecteur Sud S.A. GP France will use reasonable efforts to obtain
               any necessary consent of lessor or any other third party to such
               assignment and, upon such assignment, GP France will surrender
               occupancy of the demised premises to BIOMERIEUX. Rentals and
               occupancy costs shall be allocated between GP France and
               BIOMERIEUX pro rata to the respective portions of such year when
               each is in occupancy of the premises. GEN-PROBE  represents that
               rental payments under such lease are FF. 143,000 per year, with
               maintenance expense of FF. 19,100, and may be subject to normal
               commercial escalation.

          2.   All rights and obligations of GP France under the distribution
               agreement dated June 6, 1994 between Euralam, S.A. and GP France
               (the "Euralam Agreement"). In connection with such assignment,
               GEN-PROBE undertakes to supply products to BIOMERIEUX or to
               Euralam for the account of BIOMERIEUX as provided in Article IV
               below.

          3.   Such other contracts of GP France deemed necessary for its
               distribution of products of GEN-PROBE in France as the parties
               may agree.

     B.   Transfer of Employees.

          GEN-PROBE will cause GP France to use reasonable efforts to cause four
          employees selected by BIOMERIEUX to accept employment with BIOMERIEUX
          and BIOMERIEUX shall extend an offer of employment to them on terms
          and conditions substantially equivalent to those of their present
          employment. GEN-PROBE has caused the terms and conditions of their
          present employment to be disclosed to BIOMERIEUX by GP France and
          GEN-PROBE warrants the

                                     - 8 -
<PAGE>
          accuracy of such disclosure. GEN-PROBE shall use reasonable efforts to
          cause GP France to obtain any approvals and authorizations required in
          connection with such transfer.

     C.   Transfer of Inventory.

          GEN-PROBE shall cause GP France to permit BIOMERIEUX to inspect and
          audit its inventory and to transfer its inventory to BIOMERIEUX in
          accordance with the terms and conditions set forth in Exhibit C to the
          Distributorship Arrangements Agreement and on the basis therein
          provided, and BIOMERIEUX shall make payment accordingly. On
          termination of the Distributorship Arrangements Agreement, GEN-PROBE
          shall have the option to repurchase any inventory acquired by
          BIOMERIEUX from GP France in accordance with Section 4 of said
          agreement.

     D.   Payment for Goodwill.

          BIOMERIEUX shall pay to GP France, simultaneously with the transfers
          referred to above, the sum of [***] in respect of value of custom and
          good will in connection with the foregoing arrangements and transfers.

II.  GEN-PROBE Retention of Ownership of GP France.

     GEN-PROBE shall retain ownership of the shares of GP France. GP France
shall remain responsible for all contracts, agreements, liabilities,
obligations, debts and other encumbrances of GP France, of whatever nature, not
specifically transferred or assigned to BIOMERIEUX as provided above (the
"Retained Obligations") and GEN-PROBE shall indemnify and hold BIOMERIEUX
harmless in respect of such Retained Obligations. If GEN-PROBE proceeds to
cause the winding-up and dissolution of GP France, GEN-PROBE shall be
responsible for all income tax obligations and other costs in connection
therewith. Each Party shall be responsible for, and shall pay when due, all
applicable sales, value added or similar taxes payable by it in connection with
the transfers contemplated by this Exhibit D.

III. Non-Competition.

     Inasmuch as GEN-PROBE  is appointing BIOMERIEUX as its exclusive
distributor pursuant to the Distribution Agreement concluded between GEN-PROBE
and BIOMERIEUX of even date herewith, GEN-PROBE shall not cause or permit any
distribution of products, goods or services through GP France in such manner as
to violate such agreement.

IV.  Supply of Products as Needed for Sale to Euralam.

***Certain information on this page has been omitted and filed separately with
   the Commission. Confidential treatment has been requested with respect to the
   omitted portions.

                                      -9-
<PAGE>

          GEN-PROBE shall supply to BIOMERIEUX its requirements of products for
fulfillment of obligations to Euralam pursuant to the Euralam Agreement. Such
supply shall be pursuant to the terms of Distribution Agreement except that (1)
prices shall be $48 per kit (Acuprobe Listeria) and (2) BIOMERIEUX and
GEN-PROBE shall accelerate orders and corresponding supply in such manner as
may be necessary to permit BIOMERIEUX to make timely supply to Euralam.

                                      -10-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00043-of-00352.parquet"}]]